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ABSTRACT 
 
Background and Objectives:  
Postoperative nausea and vomiting (PONV) have forever been a complication 
of anaesthesia. Lack of efficient prophylactic antiemetic therapy may prove detrimental 
to a successful surgery and timely discharge.  There are a wide range of drugs for 
preventing PONV. This study was designed to compare the efficacy of intravenous 
ranitidine plus metoclopramide to that of intravenous ondansetron in preventing post-
operative nausea and vomiting in patients undergoing general anaesthesia. 
Methods:  
84 patients undergoing elective surgery under general anaesthesia were 
randomized into two equal groups to receive either a combination of 50 mg ranitidine 
plus 10 mg of metoclopramide or 4mg of ondansetron. Both groups of drugs were 
given intravenously half an hour prior to induction. All patients underwent 
standardized general anaesthesia with controlled ventilation. They were monitored at 
the initial first hour and for 24 hours post operatively for episodes of nausea, retching 
and vomiting which were tabulated under a scoring system. 
Results:  
When considering ranitidine and metoclopramide group: nausea was absent in 
71.43% of patients in the initial hour and 90.48% of patients in the 24 hours post 
operatively. Retching was absent in 90.48% of patients in the initial hour and in 
95.24% of patients in 24 hours post operatively. Absence of vomiting was seen in 
76.19 % of patients in the initial hour and in 95.24 % of patients in the 24 hours of 
postoperative period. 
  
In the ondansetron group nausea was absent in 71.43 % of patients in the initial 
hour and in 88.09 % of patients in 24 hours of postoperative period. Absence of 
retching was seen in 83.33% of patients in the initial hour and in 97.61% of patients in 
24 hours of postoperative period. Absence of vomiting was seen in 85.71% of patients 
in the initial hour and in 92.85% of patients during 24 hours of postoperative period. 
Conclusion:  
It was concluded from this study that the combination of ranitidine 50 mg, 
metoclopramide 10 mg was as efficient as ondansetron 4mg when given intravenously 
prior to general anaesthesia in preventing PONV. 
Key words:  
PONV; general anaesthesia; ranitidine; metoclopramide;  ondansetron.  
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INTRODUCTION 
 
Anaesthesia and surgical procedures are associated with a number 
of post-operative symptoms which leads to patient dissatisfaction with 
anaesthesia
(1 )
.The most common of these symptoms include: pain,  
dizziness, drowsiness, headache, nausea and vomiting. However the most 
common and distressing of the symptoms is pain and emesis. While it  is 
true that  lot of at tention  has  been  paid  towards  relief  of  pain, not  
much  attention  has been paid  to  the problem of  postoperative  nausea  
and  vomiting
(4 )
.  But postoperative nausea and vomiting is estimated to be 
a more critical and distressing symptom to the patient. Sometimes nausea 
and vomiting may exist even after minor and ambulatory surgery which 
would eventually delay the hospital disch arge and leave a dreadful 
experience of surgery and anaesthesia with the patient. The situation can 
be so grave that it  is  estimated that most patients are willing to pay up to 
$100 for an effective treatment
(1 )
.  
  
        Nausea  and  vomiting  have always  prevailed  with  anaesthesia  
and  one of  its  first  extensive  descriptions  was  given  by  Sir  John  
Snow  in 1848  itself. In Ether era, the incidence of PONV had been 
around 75-80%
(2 )
.  In recent large studies the incidence is stated to be 
around 25-30 %
(  2 ,  3 )
.  
 
In Laparoscopic procedures the incidence may range 
up to 53-72 %
(  2 ,  3 )
.  
The occurrence of PONV poses a challenge for surgeons and 
anaesthetists al ike and hence it is very rightly termed as “BIG LITTLE 
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PROBLEM”  (5 ) .  The problem is further  aggravated by the fact  that  there is  
no “magic bullet” that will prevent or control PONV in all aspects and in 
all patients.  
The consequences of post -operative nausea and vomiting may be 
mild, moderate or severe. While mild and moderate forms may just  
increase patient dissatisfaction, the more severe forms of nausea and 
vomiting not just increases the patient dissatisfaction, but causes also 
dehydration, electrolyte imbalance, dehiscence of wound, prolonged 
bleeding from surgical site, esophageal rupture a nd blindness. In the post -
operative period the major danger possessed by PONV is aspiration of 
vomitus leading to respiratory obstruction and aspiration pneumonia. All  
these not only lead to an increased use of medical resources but also 
consequent delay in discharge from hospital
 (4 )
.  
With the change in trend from an inpatient to outpatient care and 
with the trend towards hospital and office based medical and surgical 
enhancement, the attention towards treatment of PONV has been on the 
increase
(5 )
.  
PONV being multifactorial has been extensively studied and it is  
shown to have a decreased incidence in the recent times because of the 
refinement in surgical procedures, identification of the high risk patients,  
use of improved pre and post anaesthetic agents an d by using less emetic 
agents. Even after al l these precautions PONV still  continues to be one of 
the greatest nuisance of post anaesthesia, with the only rescue being 
pharmacological  management.  
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There are a wide range of antiemetics available to date whic h have 
evolved over the eras. These include dopamine [D 2] receptor antagonists,  
Histamine [H1] receptor antagonists, Muscarinic antagonists,  Cholinergic 
receptor antagonists,  5HT 3  receptor antagonists, alpha adrenergic agonist,  
corticosteroids, benzodiazepines, benzamides, propofol and 
butyrophenones
(2 )
.  
Ondansetron is a 5HT 3  receptor antagonist which is being used 
widely for the management of PONV and belongs to the newer era of 
drugs for PONV treatment. But for many years anaesthetists have placed 
their trust on the combination of ranitidine/ metoclopramide as a 
preventive therapy for PONV.  
          This study was carried out for comparing the effectiveness of these 
2 groups of drugs in reducing and preventing the incidence of PONV in 
patients undergoing General anaesthesia.  
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AIMS AND OBJECTIVES 
 
To compare the efficacy of ranit idine plus metoclopramide to that 
of ondansetron in controlling postoperative nausea and vomiting in 
patients undergoing general anaesthesia.  
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REVIEW OF LITERATURE 
 
 One of the earliest  and extensive reports on the phenomenon of 
post-operative nausea and vomiting had been given by John Snow as early 
as 1848, just about 18 months after the introduction of chloroform into 
anaesthesia. Historically important modes of tre atment included agents 
like wine also which was a preferred agent by the patients. The Battleys 
solution of opium has also got historical importance
(4 )
.  
The ether era had the highest  incidence of PONV, where its  
incidence ranged as high as 75-80%
(2 ,3 )
.  During this era they employed a 
number of techniques to prevent PONV. These included olive oil and 
insulin-glucose infusions.  Robert Ferguson was the first to use olive oil in 
1912, which he administered by mouth after the patient had gained partial 
consciousness. The idea behind this was that oil would absorb any 
residual ether that might be there. Brown Sequard in as early as 1883 had 
established the benefit of atropine in controlling postoperative nausea and 
vomiting when morphine was used
(4 )
.  
            The change in anaesthesia techniques and the switch over from 
opioids (and deep ether anaesthesia) to a non -opioid (or supplemented 
opioid premedication) and the usage of lighter (non -ether) anaesthesia had 
eventually led to a decrease of PONV up to 50%
(4 )
.  The refinement in the 
surgical  techniques and the better identification of the at risk patients of 
PONV have also led to a decrease of PONV
(4 )
.  And now the incidence is 
at 25-30% 
(2 ,3 )
.
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About seventy five years ago Flagg had suggested that PONV may 
result  from causes which were not entirely anaesthesia related and he also 
suggested that there are at least three different kinds of vomiting. The 
first of these may be attributed to the anaesthetics such as ether,  the 
second may be due to reflex responses and the last  may be due to opioids.  
Subsequent studies over a period of time have established a large number 
of non anaesthetic factors behind the pathogenesis of postoperative nausea 
and vomiting
(4 )
.                                                                                                                                                                                  
Over the years a number of drugs have been developed to treat  
postoperative nausea and vomiting. One of the earlier drugs to be 
produced for the treatment of PONV was the Phenothiazines. 
Phenothiazines were synthesized originally in 15
t h
 century by the dye 
industry chemists. Promethazines were synthesized in 1930 and was found 
to be beneficial in controlling emesis
 (4 )
.  Chlorpromazine was synthesized 
by Charpentier in 1949, though i t had anti -emetic property, its use was 
limited due to its  side effects of sedation and hypotension. Perphenazine 
and Prochlorperazine are other drugs extensively used in the management 
of PONV
(4 )
.  
There has been a volley of systemic reviews in the world literature 
which dealt with PONV. However still  to this date there is no specific 
management for PONV which would be ideal to all patients. Ever since 
the Halothane t imes, in 1956 there has been a litt le change in th e 
PONV
(4 )
.  
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So now the question is why the absolute mechanism or the absolute 
remedy to this wide spread and big lit tle problem is not known? There are 
four factors to explain this
(4 )
:  
1.  Complexity of the problem :   
The variables and factors associated with PONV are so many, such 
that to study them independently and to assess the effects of an 
intervention would require a large number of patients and a large number 
of well controlled trials.  
2.  Inadequate quantification of the problem:  
Though there have been a large number of cl inical trials,  none of 
them have accurately quantified the problem in terms of nausea, vomiting 
or retching.  
3.   Inadequate antiemetic regimen:  
Emesis occurs as a common symptom in disease or as a side effect 
of therapies e.g. cytotoxic chemotherapy, radiotherapy. It can also be a 
naturally occurring phenomenon in motion sickness and pregnancy. The 
physiology of the emetic mechanism is not well  researched. The 
predominant mechanism of each type of nausea and vomiting should be 
identified for its  effective antiemetic treatment.  
4.  Animal Model  :  
The lack of adequate animal study model, limits the study of 
physiology and pharmacology of the mechanism of PONV. Many species 
of experimental animals such as rats and rabbits do not vomit upon 
stimulation. However monkeys and dogs do react to the same range of 
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emetic stimuli as men especially with cytotoxic drugs and radiation. 
However they cannot be st imulated to suffer from pregnancy, motion 
sickness and post-operative and post -anaesthetic emesis. So now the 
question arises why this much importance is given to this l it tle problem. 
This is because of the consequences that are produced by PONV which 
may be classified into physical, metabolic and psychological
( 9 )
.  
Physical  
Retching and vomiting are fairly violent activities which may cause 
stress and strain on certain structures if they are present for a prolonged 
amount of time. Results of such stress can lead to oesophageal tears 
leading to mediastinitis and may also lead to Boerhaave Syndrome and 
Mallory Weiss Syndrome (that is the rupture and hemorrhage of the 
oesophagus respectively), rib fractures can also occur, rupture of the 
cutaneous vessels in the upper body, fatigue and strain of muscles can 
occur and gastric herniation can also occur. There may also be wound 
dehiscence and bleeding at the operative site which may lead to hematoma 
formation. There may also be undue increase in the intracranial pressure 
and intraocular pressure. In case of plastic surgeries there ma y be 
bleeding from skin flaps. The strain and stress on wound may eventually 
lead to an increase in the postoperative pain. Another fatal complication 
of PONV is aspiration of vomitus which may lead to aspiration pneumonia 
and may also trigger the cardiore spiratory reflexes and thereby increase 
the chance of morbidity and mortality
(9 )
.  
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Metabolic  
With persistent vomiting, dehydration, fluid and electrolyte 
imbalance may occur especially when considering the pediatric age 
group
(9 )
.  
Psychological  
Patients may be so distressed by the presence of PONV that i t  may 
produce a general aversion to surgery and anaesthesia. The patient may 
expect the same complication to occur with subsequent surgery. The 
eventual consequence of PONV is delayed hospital dis charge and this will  
consequently increase the financial burden because the patient will 
require more time in the recovery room and need more care from the 
medical faculty. This will eventually put a burden on the patient as well  
as the health system as a whole
(9 )
.
 
 
Postoperative nausea and vomiting (PONV) became a commonly 
known and studied phenomenon after the landmark review by Watcha and 
White 
(2 )  
in which they explained its etiology, treatment and prevention.  
 
PHYSIOLOGY OF NAUSEA AND VOMITING 
Following are the definitions of each associated term:  
1.  Nausea:  
Nausea is a subjective, unpleasant sensation of a need to vomit and the 
feeling that vomiting is imminent. It  occurs in waves either preceding 
vomiting or in isolation.  
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2.  Retching:  
This is an expulsive muscular effort  with spasmodic rhythmic 
contraction of diaphragm, chest wall and abdominal wall  muscles but 
without the actual act of expulsion of stomach contents
 (2 ,3 )
.  These are 
also called as ‘dry heaves’.  
3.  Vomiting:  
This is the forceful expulsion of upper gastro intestinal contents 
through mouth which is brought about by the powerful and sustained 
contraction of abdominal muscles, descent of the diaphragm and the 
subsequent opening of the upper esophageal sphincter. Vomiting is 
different from gastroeosophageal reflux or regurgitation. 
Gastroeosophageal reflux or regurgitation are neither forceful nor do they 
involve the muscular activity as in retching or vomiting.  
         Vomiting is actually a naturally occurring defense mechanism of the 
gastrointestinal system which is brought in action on ingestion of toxins 
and irritants . It  aims to reduce the further intake of the toxins. But 
clinically vomiting (especially the postoperative nausea and vomiting) is  
considered as undesirable mainly becaus e of the consequence they 
produce.  
          Why should anaesthesia and surgery induce nausea and vomiting?  
The reason for this is just like in many other clinical situations where 
nausea and vomiting can occur, some aspects of surgery and anaesthesia 
can also trigger the emetic detectors.  
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MECHANISM OF NAUSEA AND VOMITING :  
          The mechanism of vomiting has 3 major components
(4 )  
:  
I.  Emetic detectors  
II.  Integrative mechanism  
III.  Motor outputs  
I.  Emetic Detectors (4 ):  
These are detectors located in gut,  chemoreceptor trigger zone and 
elsewhere which upon stimulation sends activated impulses leading to 
emesis within 20 seconds. The detectors are the following:  
Abdominal Visceral Afferents :  
      These are the detectors present   in the gut. They are vagal afferents 
and are of two types:  
a. Mechano receptors :   
They are located in the gut muscular wall . These get  activated when 
there is contraction and distention of the gut as in times of over eating,  
surgical  manipulation and physical  damage.  
 b. Chemoreceptors:  
These are located in the mucosa of upper gut and are very sensitive 
to the chemical stimuli of the intraluminal environment. They respond to 
stimuli such as mucosal stroking, acid, alk ali, temperature, toxins (e.g.  
staphylococcal entero toxin) and other noxious chemical stim uli . The 
substrate for the polymodal mucosal receptors is not well known but it  is 
postulated that an arrangement like that  of the taste buds or the carotid 
body, (having detector cells) is present which responds to a range of 
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stimuli by releasing the neurotransmitter. In the intestine 
enterochromaffin cells acts as detector cells
(4 )
.  
Area postrema receptors:  
Another detector which is one of the most important anaesthesia 
associated detector lies in the area postrema. The area postrema is a U 
shaped circumventricular organ of the brain which is a highly vascular 
area.  It lies at the caudal part of fourth ventricle and contains the 
specialized cells termed as chemoreceptor trigger zone (CTZ).  Wang and 
Borison were the first to demonstrate the chemoreceptor trigger zone. 
CTZ is deficient in blood brain barrier which makes it ideal  for detecting 
the blood borne toxins / drugs or the circulating toxins in the CSF. It then 
activates the vomiting centre in the medulla.  The area postrema is rich in 
dopamine opioid and serotonin receptor (5HT 3). The CTZ contains 
abundant opiate receptors, enkephalins, 5HT 3  receptors and also dopamine 
receptors. This zone is said to be responsible for the vomiting stimuli  
associated with opiates, cardiac glycosides and motion sickness. They 
receive afferent inputs from vagal and glossopharyngeal nerve which 
provides the information on lung volume, gut content and blood 
pressure
(4 )
.  
Nucleus solitarius is  another detector lying close to vomiting centre 
which is rich in encephalin, muscarinic,  cholinergic, histamine receptors. 
All these receptors can transmi t impulses into the emetic centre. Hence 
the blockade of all  these receptors is  the mo st important mechanism used 
in the current antiemetic drugs  
13 
 
Vestibular system: 
Vestibular labyrinthine is involved in the nausea and vomiting 
occurring during motion sickness. They induce vomiting by motion 
stimuli which is conducted by the eight cranial n erves. The possibility of 
labyrinthine stimulation should be borne in mind while the patients are 
shifted onto the trolleys for transportation after surgery because this may 
act as additional input to induce emesis.  
There is only patchy evidence if labyrin thine system has any 
association with drug induced nausea and vomiting  
Higher influences:  
The exact mechanism of the influence of the higher centres in  
nausea and vomiting is unclear but there is little doubt that these centres 
(e.g.  Limbic system) do have a role in inducing nausea and vomit ing.  
Impulses from higher centre (e.g.: limbic system) and visual cortex can 
cause vomiting by having a more of  facilitatory role in stimulating the 
brain stem emetic centre and seems to have little role as the  primary 
detectors of the emetic stimuli .  
Miscellaneous inputs
(4 )
: 
Nausea and vomiting maybe easily brought about by activation of many 
other parts of the body:  
1.  Unpleasant tastes can induce both nausea and retching. However it is 
not clear if  this is  due to a primary response or is  a secondary response 
in association with previous illness and thereby a result  of prior 
experience (learned aversion).  
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2.  Nausea and gagging can also be brought about by the mechanical 
stimulation of the pharyngeal afferents brough t to the brain stem by 
the glossopharyngeal nerve.  
3.  Ventricular cardiac afferents may also induce nausea and vomiting and 
this may be the underlying reason for nausea and vomiting found 
before or during myocardial  infarction.  
4.  Tympanum can be st imulated which in turn activates auricular branch 
of vagus called as the Arnold’s nerve or the Alderman’s nerve, which 
induces nausea and vomiting  
         The inputs from all these centres are brought to the vomiting centre 
where they undergo integrative mechanism. Before moving onto the 
integrative mechanism the vomiting centre is  considered briefly:  
It  is generally accepted that a discrete area located at the reticular 
formation of the medulla acts as the vomiting centre and is responsible for 
controlling and coordinating nausea and vomiting. A complex range of 
interactions occur here which eventually results in vomiting which is a 
complex reflex. The interactions occurring here involves the reticular 
formation along with other areas like the nucleus tractus solitarius and the 
autonomic nuclei especially the vagus nerve. Along with this the vomiting 
centre also receives the afferent inputs from the receptors in the 
gastrointestinal tract, peripheral pain receptors (which are activated 
during trauma), the pharynx during the gag ref lex, vestibular system 
(which are stimulated during motion sickness), the chemoreceptor trigger 
zone (which is activated by drugs/toxins) and finally the cerebral cortex. 
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Some 40 neurotransmitters are involved in the neurochemistry of the 
vomiting centre, which makes the process of controlling nausea and 
vomiting even more difficult.  
II INTEGRATIVE  MECHANISM
(4 )
: 
Vomiting is a motor programme which requires an integrative 
mechanism involving coordinat ion between many physiological,  
autonomic and somatic components.  The coordination of motor 
components occurs in the brain stem.  This seats the vomiting centre in 
the medulla oblongata. The vagal motor neuron supplying the gut and 
heart originate in the b rain stem at the dorsal  motor vagal nucleus and 
nucleus ambigus. Also the dorsal and ventral respiratory   groups 
regulating the phrenic nerve output from the cervical spinal cord are 
located here and so are the presympathetic neurons which regulates the 
sympathetic tone in the blood vessels and heart .The coordinated output of 
these nuclei produces the characteristic vomiting pattern
(4 )
.  
III MOTOR OUTPUT
(4 )
: 
Vomiting is a motor event involving both the autonomic and 
somatic division. Though ejection of upper GI contents is the most 
obvious component of vomiting, it  actually occurs after going through a 
series of motor events. It consists of three phases:
 
Preejection phase
(4 )
: 
This is associated with a sense of nausea with several visible signs 
such as cold,  sweating, pupillary dilation, cutaneous vasoconstriction, 
tachycardia and decreased gastric secretion. These are all mediated by 
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sympathetic nerves. There is also salivation which is due to 
parasympathetic stimulation.  
Just before the ejection phase th ere is relaxation   of the proximal 
stomach. This is  brought about by the action of vagal efferent nerves 
which stimulates the post ganglionic n euron in the stomach wall to release 
neurotransmitters like vasoactive intestinal polypeptide (VIP) or nitric 
oxide. The next event is retrograde giant contractions which propels 
contents from the mid small intestine towards the stomach. This is also 
under the vagal control and is mediated by the neurotransmitter 
acetylcholine. The gastric relaxation confines the gastric contents to the 
stomach while the retrograde giant contractions helps load all the 
contaminated gastric contents in the stomach ready for ejection. The pre -
ejection phase may or may not be followed  by the ejection phase
(4 )
.  
Ejection phase
(4 )
: 
This phase consists of retching and vomiting, with the expulsion of 
gastric contents occurring only during vomiting.  
  The phenomenon of retching can be explained as rhythmic and 
synchronous contraction of diaphragm and abdomen. As the antral portion 
of the stomach contracts, the proximal portion relaxes leading to 
oscillation of contents between the stomach and oesophagus. The hiatal  
portion of diaphragm does not relax during retching.  There is increase 
only in the intra-abdominal pressure with a decrease of intra thoracic 
pressure during retching.  
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During vomiting however,  hiatal portion of diaphragm relaxes and 
also abdominal muscles contract forcefully.  Thus the actual gastric 
contents expulsion occurs by com pression of stomach between the 
descending diaphragm and the contracting abdominal muscles and along 
with this the lower esophageal sphincter  relaxes .There is  increase of 
both intrathoracic and intragastric  pressure along with reverse peristalsis  
which  leads to expulsion of gastric contents through  the open mouth .  
Post ejection phase:  
This  involves  autonomic  and  visceral  responses  that returns  the  
body  back  to  quiescent  phase  with  or  without  nausea
(4 )
.  
FACTORS RESPONSIBLE FOR PONV  
Factors responsible for postoperative nausea and vomiting may be 
broadly divided as two:  
I)Non anaesthetic  factors  
This again consists of  A) patient factors and B) procedure factors  
II).  Anaesthetic factors:  
This again consists of A) the experience of the anaesthetist B) 
preanaesthesia period C) gastric suction D) intubation E) anaesthetic  
technique F) post -operative period.  
NONANAESTHETIC FACTORS  
A. PATIENT FACTORS: 
 Susceptibility  
Susceptibility or higher predisposition of some patients to vomiting 
even with slightest stimulation is an established factor for PONV. It was 
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observed by Purkis that the chances for PONV had been increased up to 
three folds in patients with previous history of PONV. This may be due to 
psychological factors in some while in other s this may be due to a 
variation in the development of the vomiting reflex 
(2 ,3 ,6 )
.  
Sex 
Emetic symptoms are about 2-4 times more common in females.  
This holds true even for postmenopausal women over 65 years.  The 
symptoms may also be more severe in the fe male patients than in the male 
patients. This high incidence of PONV in women is  probably due to 
female hormones. The variations in the plasma pr ogesterone and serum 
gonadotropin may be responsible for this. The incidence is higher in  the 
luteal  phase and is maximal  on the 4
t h
 and 5
t h
 day of the menstrual cycle.  
This gender difference does not hold much significance beyond the eight 
decade of life, again suggesting the role of gonadotropins in the greater 
incidence of PONV in women
(2 ,3 ,6 )
.  
Age 
PONV incidence changes with age. In infants the incidence may 
only be about  5%, it may increase to 20% in children below  5 years,  
while the incidence may increase  up to 34 -51% in the late childhood  (6 -
16 years ) thereafter  it  may remain const ant or may decrease  to 14 -40% 
during  the adult hood
(1 ,2 ,6 )
.  In general  children are twice as likely as 
adults to experience PONV.  
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Weight 
       There is a positive correlation between PONV incidence and body 
weight. Obese patients have higher inciden ce of PONV. This is because:  
1)  The adipose tissue acts as a reservoir that loads the inhalational  
anaesthetic agents, which is eventually released back into the blood 
stream even after stopping the supply.  
2)   Also obese patients have a larger residual gastric  volume and an 
increased incidence of gastro esophageal reflux. They also have 
greater chance of gallbladder and other gastrointestinal diseases,  all  
of which may predispose the obes e patients to greater incidence  of 
PONV. 
3)   Compared to the non-obese patients ,  obese patients are well  
documented to have difficult airways and hence they have greater 
chances of gastric inflation during attempted face mask venti lation 
to maintain saturation
(2 ,  3 ,  7 )
.  
History of Motion Sickness and or Previous PONV 
        Patients with previous experience of PONV are three times more 
likely to experience PONV again. Patients susceptible to motion sickness 
are also prone to PONV
(2 )
.  
Anxiety 
Preoperative anxiety leads to increased incidence to PONV. The 
alpha adrenergic stimulation has been postulated as an explanation for  
this phenomenon. Anxious patients swallow excessive amounts of ai r 
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before surgery leading to an increased gastric volume which may 
predispose for post -operative emesis 
(2 )
.  
Gastroparesis  
Delayed gastric emptying secondary to underlying disease may 
increase the risk of PONV. These conditions include gastrointestinal  
obstruction, pyloric stenosis, chronic cholecysti tis, intrinsic neuropathies, 
neuromuscular disorders and myopathies. Gastric hypomotility 
complicates conditions like progressive muscular dystrophy, amyloidosis,  
scleroderma, anaemia, increased abdominal pressure , familial visceral  
myopathies and pregnancy.  Along with gastroparesis patients with 
diabetic mellitus may also be associated with pylorospasm, isolated antral 
hypomotility and hence diabetic patients have an increased incidence of 
PONV. Premedication with opioids and barbiturates given for anxiolysis 
may lead to delay in gastric emptying thereby predisposing to post -
operative emesis.  
Smokers 
Nonsmokers are at least two times more prone to postoperative 
nausea and vomiting when compared to smokers. This p ossibly reflects on 
the nicotine induced increases in the synaptic concentration of dopamine 
via GABA-ergic pathway inhibit ion
(2 ,3 )
.  
Pregnancy 
The entire gastrointestinal tract undergoes changes during 
pregnancy. There is gastric hypomotili ty,  increased se cretions, along with 
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a relaxed gastroesophageal junction during pregnancy all of which 
increases the incidence of regurgitation and PONV.
(
 
1 ,2 ,4 ,6 )  
B. SURGICAL/ PROCEDURE RELATED FACTORS:  
General effects:  
Gastrointestinal motility: The anesthetic agents us ed already reduce 
the gastrointestinal motility,  the surgery also has a similar effect and it 
outlasts the duration of surgery. The end result of combined effect of 
anaesthesia and surgery is a twofold reduction in the gastric emptying. 
Due to surgery induced delayed gastric emptying there will be 
accumulation of secretions and this may induce reflux of bile into the 
stomach and there may also be gas accumulation which may be accounted 
to anaesthetic technique, air swallowed before surgery or may be 
endogenously produced. All these may eventually lead to the activation of 
gastrointestinal  visceral afferents including nociceptors (in case of a 
strong stimulus). When the patient regains consciousness, the distensile 
stimuli will cause upper abdominal discomfor t which may lead to nausea 
or vomiting. The effects of surgical trauma will persist  beyond the 
surgery period and may extend into the postoperative period. Therefore 
though patient has recovered from anaesthesia, they may still  have a 
reduced gut motility and therefore maybe unable to cope with a normal 
meal 
(2 ,3 ,6 ,1 0 )
.  
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Endocrine effects:  
Apart from adrenaline, another hormone released due to surgical  
stress response is vasopressin (AVP) which has a close association with 
nausea rather than vomiting
(1 0 ) .
 
Site of Surgery 
The type of surgical  procedure influences the incidence of PONV 
irrespective of the anaesthetic  technique used.  Considering the adult  
population the highest incidence of PONV was reported in women 
undergoing laparoscopic ovum retrieval procedures which are estimated to 
be about 54%. This is followed by laparoscopy having an incidence of 
34%, dental  extractions having an incidence of 16%, dilation and 
curettage of uterus having an incidence of 12% and knee arthroscopies 
with an incidence of 22%. High incidence of PONV has also been 
observed after extracorporeal shock wave lithotripsy, stomach, duoden um 
and also gallbladder operations.  Ear surgery, eye surgery (e.g. Strabismus 
surgery), plastic, oral and head and neck surgery also have higher chances 
for increased PONV 
(2 ,  3 ,  6 )
.  
Duration of Surgery :  
Patients having a long duration of surgery, i .e.,  mo re than 3 hours 
have a greater incidence of post -operative emesis. This is because during 
a longer surgery, there is a simultaneous longer period of exposure of 
patients to lipid soluble, emesis producing inhalationa l agents and 
intravenous agents
(2 ,  3 ,  6 )
.  
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Reasons for Surgery: 
In some patients nausea and vomiting are already a component of 
the disease for which they are being treated ( e.g..  raised intracranial  
tension, G.I obstruction). In these patients the emetic centres will already 
be in a sensitized state 
(2 ,  3 ,  6 )
 
II. ANAESTHESIA RELATED FACTORS 
A.  Experience of the anaesthetist:  
Vigorous posit ive pressure ventilation during facemask ventilation 
causes increased gastric dilation and will predispose a patient to PONV. 
This commonly occurs in hands of an inexperienced anaesthetist and in 
obese patients in whom mask ventilation may prove difficult
(2 ,4 )
.  
B. Preanaesthesia including preoperative fasting and 
premedication.
 
Preoperative Fasting: 
 
        A 6-8 hour fasting period is mandatory to reduce the risk of 
aspiration of gastric contents during induction because ingestion of solid 
food causes distention of the gut and increases the release of hormones 
sensitizing the vomiting reflex.
  
Intake of food shortly before the 
induction of anaesthesia is  a well -documented reason to cause emesis both 
intra-operatively and post -operatively. The volume and chemical 
composition of the meal taken influences the rate of gastric emptying, 
with fatty meals being emptied relatively slowly. Moreover, any 
associated trauma may further lower the gastric emptying due to 
sympathetic activation. Food activates the abdominal vagal afferents and 
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this effect which when combined with the effect of anaesthesia on the 
CNS may stimulate the emetic reflex
(2 ,  3 ,  6 ,1 1 )
.  
Preanaesthetic Medication :  
        Premedication using opioids increase the incidence of PONV by 
stimulating opioid receptors regardless of the route of administration. 
Opioids can directly stimulate the area po strema to a great  degree and 
increase the incidence of PONV. However with higher doses opioids can 
depress the CNS and the vomiting centre. Opioids can also decrease the 
gastrointestinal motility, prolonging the gastric emptying time and 
thereby increasing the chances of PONV. Opioids also enhance the release 
of serotonin from the small intestine and hence contribute to PONV. 
Opioids can also increase the release of vasopressin (ADH) from posterior 
pituitary, which is not only associated with nausea and vom iting, but also 
has an inhibitory effect on gut motility
( 3 , 6 ,1 0 ,11 )
.  
Opioids can sensitize the otic and vestibular areas and hence 
predispose to PONV. Stimulation of endolymph  present in the inner ear 
due to patient movement postoperatively can increase the frequency of 
opioid induced emesis. Therefore during movement of patients from cart 
to chair, chair to standing, ambulation or during car ride back home can 
all increase chances of PONV in outpatients. These side effects may last  
up to 6 hours after opioid administration
( 3 ,6 ,1 0 ,1 1 )
.   
Scopolamine (hyoscine) or atropine given along with opio ids as 
premedication reduces the incidence of PONV in comparison to opioids 
being used alone. Both atropine and scopolamine being tertiary amines 
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cross the blood brain barrier and can hence exert  their antiemetic and 
antimotion sickness effects. Glycopyrrolate being a quaternary amine does 
not cross the blood brain barrier and hence does not have any antiemetic 
or antimotion sickness effects.  Scopolamine rather than atropine is most 
routinely combined with morphine as premedication as i t  has greater 
sedative effects
.  (3 ,  6 )  
       Benzodiazepines, e.g., midazolam are  used as premedication for  
sedation because they decrease the release of catecholamine and hence 
decrease the incidence of PONV. 
 
C. Gastric Distension and Suctioning: 
Nasogastric suctioning is done to remove secretions, blood and air 
from stomach. Surgeries involving mouth, nose, oropharynx may lead to 
swallowing of the blood . Blood in stomach is a strong emetogenic 
stimulus and is difficult to be treated by just giving antiemetic medication 
alone. The removal of this blood by gastric suction or emesis helps in 
providing relief 
(2 ,  3 )
.  
  Also in cases of gastric distension (i.e.  in GI obstruction, ileus) 
gastric suction decreases PONV. PONV following GI surgery or air 
inflation into the stomach, as occurring during vigorous mask ventilation 
can be reduced by using gastric suctioning . Presence of oral airway, 
pharyngeal suctioning or a continuous presence of nasogastric tube in 
postoperative period stimulates the gag reflex and leads to increased 
gagging and retching due to stimulation of glossopharyngeal nerve and 
eventually increases the chance of PONV 
(2 ,  3 ,  8 )
.  
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D. Intubation 
During the insertion of the airway device through the oropharynx, 
the pharyngeal afferents (predominantly the glossopharyngeal nerve) may 
be stimulated. This stimulation can induce gagging reflex and can also 
cause retching and vomiting
(1 1 )
.  
E) Anaesthetic Techniques :  
1.  General Anaesthesia:  
a)  IV Induction agents:  
Different IV induction agents are associated with differing degrees 
of PONV. Agents producing smoother recovery (i.e. , Thiopentone, 
Propofol) have a lower incidence of PONV when compared to rapid 
recovery producing agents (methohexital) and also from those producing 
higher incidence of excitatory effects during or after anaesthesia (e.g.,  
etomidate, ketamine). Thiopentone when used with Nitrous Oxide  in 
minor gynaecological surgery have an incidence of PONV of 12%. 
Etomidate used in the form of continuous infusion during balanced 
anaesthesia increases the incidence of PONV
(2 ,  3 )
.  
Ketamine when used for induction and or maintenance of 
anaesthesia have higher chances for PONV than when thiopentone and 
nitrous oxide are used. This is due to rele ase of endogenous 
catecholamine. 
         Propofol is frequently used for total intravenous anaesthetic 
technique and have proved to lower the incidence of P ONV. Propofol is 
structurally unrelated to any of the other available intravenous agents.  
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Therefore propofol is very popular during outpatient procedures because 
of its smoother recovery characteristics including rapid emergence  and a 
lower incidence of PONV
(2 ,  3 ,  6 )
.  The incidence of PONV is as low as 1-
3% as compared to the 10-15% found with the other agents. However 
studies have shown when propofol is used in a Propofol -nitrous-oxide-
inhalation agent combination, the incidence of PONV is relatively highe r 
than when used alone
 (2 ,  3 )
.  
b. Inhalational anaesthetic agents : 
Nitrous oxide 
Nitrous oxide is associated with a  high incidence of PONV ranging 
from 49% to 67% depending on the percentage of end tidal concentration. 
Nitrous oxide stimulates PONV by the following three mechanisms:  
1.  Direct stimulation  of vomiting centre by interacting with opioid 
receptors and stimulat ion of the sympathetic nervous system by 
releasing catecholamine.  
2.  Middle ear pressures may be changed resulting in traction of the 
round membranous window leading to vestibular system 
stimulation.  
3.  Distension of air containing spaces like stomach, large an d small 
intestines and gall  bladder.  
There is  significant increase of PONV incidence in patients being 
anaesthetized with a balanced anaesthesia technique containing nitrous 
oxide/ opioid/ oxygen/ muscle relaxant than with those patients 
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anaesthetized with an inhalational technique. The incidence of PONV is  
still  lower when total intravenous technique is used 
(2 ,  3 )
.  
Volatile anaesthetic agents:  
Older anaesthetic agents like diethyl ether or cyclopropane have 
higher incidence of PONV ranging up to 75 –  85%. The newer inhalational 
agents like halothane / isoflurane/ enflurane/ desflurane and sevoflurane 
have a lower incidence of PONV.  This is associated to the release of 
endogenous catecholamines  
(2 )
.  
c) Neuromuscular blocking agents:  
Neuromuscular blocking agents do not have much effect  on PONV 
but the reversal agents i.e. the anticholinesterase drug (e.g. neostigmine) 
and anticholinergic drugs like atropine and glycopyrrolate is associated 
with a higher incidence of post-operative emesis and nausea. When 
anticholinesterases are used alone, there is a further increase of PONV 
incidence because these agents will  increase the gastric motility.  The 
increased bowel activity is  unchanged by the anticholinergic  agent (be it 
atropine or glycopyrrolate) used in combination with the 
anticholinesterases
 (3 )
.  However when the combination of 
anticholinesterases and anticholinergic drugs are used in the usual doses 
emesis usually does not occur
(3 )
.  
Balanced anaesthesia:  
Compared to the use of total intravenous or inhalational techniques,  
the use of nitrous oxide –  opioid relaxant technique is found to have a 
greater incidence of PONV. This is  greatly attributed to the administration 
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of opioid –  nitrous oxide combination and a direct effect of these a gents 
on CTZ. Morphine, in its analgesic doses does not cause much nausea in 
the recumbent position but however have an emetogenic effect upon the 
movement of patient due to a vestibular component to opioid  induced 
emesis.  This analgesic induced emesis ma y be decreased if an alternative 
drug such as Non-steroidal anti-inflammatory drugs can be used. 
Ketorolac (NSAID) can be effectively  used in place of morphine or 
fentanyl  especially in the outpatient setup
(2 )
.  
2) Spinal /  Epidural Anaesthesia (central neuraxial blockade)  
     Spinal anaesthesia is associated with a PONV incidence of 10 –  20%. 
The factors associated for higher incidence of PONV are:  
Height of the blockade:  
When the block extends to or above the T 4  dermatome, it  is  
associated with a higher incidence (3.9 times greater) compared with a 
lower level block. This is related to a greater sympathetic blockade, which 
will lead to an unbalanced parasympathetic influence.  
Pain :  
Appreciation of pain during surgery increases the incidence of 
PONV. 
Hypotension :  
When the arterial blood pressure declines rapidly to less than 80 
mmHg or decreases to more than 40 mmHg from baseline blood pressure 
occur, it  is often associated with nausea.  It is postulated that this is due 
to hypoxemia at the vomiting centre because this event could be 
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attenuated by administration of 100% oxygen. Also the use of IV atropine 
decreased the emesis associated with hypotension suggesting that vagal 
stimulation also plays a role
 (3 )
.  
Local anaesthetic used:  
Local anaesthetic alone is not found to have high PONV incidence 
but when given with phenylephrine or adrenaline PONV is increased.
(3 )  
Resting heart  rate  
Patients having a resting heart rate of more than 60 beats per 
minute have a higher incidence of PONV as compared to patients whose 
heart rate is less than 60 beats per minute. Preoperative anxiety may have 
a role in increasing postoperative nausea and vomiting.  The resulting 
nausea and vomiting during epidural and intrathecal block is mainly due 
to:  
 Reduced cerebral blood flow secondary to systemic hypotension 
(due to vasodilatation).   
 Vagal stimulation occurring during surgical procedures e specially 
during intraabdominal , gastrointestinal manipulation as in caesarean 
section, hysterectomies,  colon operation.  
 Increased gastrointestinal peristalsis because of the preganglionic 
sympathetic blockade.  
Compared to spinal,  epidural anaesthesia has a lower incidence of  
PONV. Intrathecal and epidural  opioids and/or local anaesthetic injection 
for post -operative pain relief is a common practice now. When 
hydrophilic opioids like morphine are being used the incidence of PONV 
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is higher due to rostral  spreading of the drug from injection site to CTZ 
and vomiting centre.  However, the lipid soluble drugs like fentanyl have 
less of rostral spread. When equipotent doses are used incidence of emesis 
after epidural or intrathecal injection is similar.  
(3 )
 
3)  Regional anaesthesia (peripheral nerve block)  
Incidence of PONV after peripheral regional anaesthesia is  lesser 
when compared with that of central neural blockade. Bonica noted that on 
supplementing regional anaesthesia with general anaesthesia the incidence 
of PONV increased to a much greater value than the combined values of 
the two techniques separately.  
(6 )
 
4)  Monitored anaesthesia care:  
       Many procedures can be done using just local anesthetics and 
intravenous analgesia sedation technique (e.g.  Cataract extractions, breast 
biopsies, cosmetic plastic surgery, endoscopy etc.). Though there is a 
reduced incidence of emesis in these patients, still  they are not 100% free 
of PONV risk
(3 )
.  
F. Post-operative factors:  
Pain: 
Pelvic and visceral pain is  a common reason for PONV. Anderson 
and Kronig observed that when pain was relieved most of the time this 
relieved the associated nausea also, which increased if naloxone reversed 
the opioid mediated pain relief. There is also a vestibular component,  
because vestibular disturbances at the time of pati ent movement and 
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during early ambulation (especially following the use of opioids ) 
contribute to an increased incidence of PONV
(2 ,3 )
.  
Dizziness: 
 
PONV is higher in patients who have dizziness. This may be due to 
the orthostatic hypotension during central  neuraxial blockade secondary to 
unrecognized hypovolemia. Orthostatic hypotension  (secondary to 
dehydration due to inadequate fluid replacement), visual stimuli  and 
psychological factors may further increase PONV. Greater vagal tone may 
aggravate the dizziness and nausea and may also reduce the medullary 
blood to CTZ. Correction of pre -existing fluid and electrolyte imbalance 
and also a proper perioperative intravenous hydration must be done, so 
that the fluid administration intra operatively and post opera tively will be 
adequate to maintain a urine output of 0.5 ml/kg/hr
 (2 ,  3 ,  6 )
.  
Ambulation:  
Sudden movement or changes in position or transporting of patient  
from the theatre to the ward may precipitate nausea and vomiting, 
especially in those patients who have received opioids. This is due to the 
sensitization of the vestibular system to motion induced nausea and 
vomiting. 
(2 ,  3 ,  6 )  
Oral intake:  
The t iming of starting the oral intake post operatively influences 
the chances of PONV. Martin et al  found restri cting the oral  intake during 
the first 8 post-operative hours caused a significant reduction of PONV
(2 ,  
6 )
.  
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 RISK ASSESSMENT OF PONV
(1 2 )
: 
PONV is very much multifactorial. Hence many studies and 
researches have been conducted and analyzed with the hope of at least  
developing a method to assess and quantify  the risk factors that increase  
the chances of PONV
(1 2 )
.  
The first form of such a complete study was conducted by Palazzo 
and Evans in the United Kingdom who applied multiple logistic regression 
analysis in 148 patients undergoing minor orthopedic surgery. One year 
later in another study conducted by Cohen MM et  al consist ing of 1600 
patients   carried out over four centres in Canada, logist ic regression was 
applied to the data.  The importance of these studies was  that they could 
establish the risk factors and independent predictors of PONV. However 
no standardization of the predictors of PONV was published.  The 
breakthrough in this came following two studies conducted by two groups 
independently:  
One of the studies was by Koivuranta and colleagues while another 
study was by Apfel  and colleagues. The first of the  two studies to be 
published was the one by Koivuranta which developed a simplified model 
consisting of five of the strongest predictors. They included  
1.  Female gender  
2.  Previous experience of PONV 
3.  Duration of operation lasting over 60 minutes  
4.  Previous history of motion sickness  
5.  Nonsmoking patients  
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When 0, 1,2,3,4 or 5 of these independent predictors were present the risk 
for PONV was:  
             17%, 18%, 42%, 54%, 74%, 87% 
A cross validation of this study with the study conducted by Apfel 
proved that risk factors from one centre were able to predict the PONV 
from the other centre and they also found that a simplification of  the 
existing score did not weaken the discriminating power.  They then 
combined a simplified scoring system.  
Their simplified scoring system consisted of four predictors of risk : -  
i . Female gender  
ii .  History of previous PONV or motion sickness  
iii .  Nonsmoking patients  
iv.  Use of opioids post  operatively 
If zero,  one,  two, three or four of the risk factors were there, the 
incidences for PONV were 10%, 21% , 39%, 61% and 79%.  
This scoring was developed for PONV prediction  in inpatients.  
Another scoring system was developed by Chung et al for considering the 
outpatients. This was a more complex predictive value which included 
also the type of surgery for the risk factor. This was however an inferior  
scoring system compared to the simplified risk scores.  
These models gave the prediction scores in the adult population and 
were not applicable to the paediatric patients. Therefore Ebehart  and 
colleagues developed a simplified risk scoring in the children that 
predicted POV. They took into consideration four variables  
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1)  Duration of surgery more than or equal to half an hour  
2)  Age greater than or equal  to three years  
3)  Strabismus surgery 
4)  A history of previous POV or P ONV in immediate family 
The presence of 0,  1, 2, 3 and 4 risk factors showed a POV 
incidence of 9%, 10%, 30%, 55% and 70% respectively  
TREATMENT OF PONV 
The treatment modalities available for treatment of PONV can be 
broadly classified into non pharmacological and pharmacological  methods 
 Non –  pharmacological approach  
 1. Acupressure or acupuncture of P 6  point:  
      This method is used most often in the prevention of nausea in 
pregnancy, cancer chemotherapy and also in PONV. This is performed at  
the Neiguan point or P 6  which is situated between the tendons of Palmaris 
longus and flexor carpi radialis  longus and measured at 2 Chinese inches 
from the distal  skin crease. One Chinese inch is the width of the 
interphalangeal joint of the thumb (i.e.  at  3 finger breadth below the 
crease of hand wrist)  
         Dundee et al investigated the effect of invasive acupuncture and P 6  
acupressure (by applying 10 Hz of electrical and manual stimulus 
respectively) applied for 5 minutes at  the time of premedication. He 
observed that there was a considerable reduction in the incidence of 
postoperative nausea and vomiting especially in the first 6 postoperative 
hours when compared to the controls.  
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         P6  acupressure was as effective as the P 6  acupuncture over the early 
post-operative period (that is in the first 0 to 1 hour) but it  has lesser 
effect than the P 6  acupuncture over the 1 - 6 hours of postoperative period. 
This method was found to be as effective as injection metoclopramide 10 
mg given intravenously or  injection cyclizine 50 mg given intravenously.  
On being compared with prochlorperazine, P 6  pressures reduced nausea 
but not vomiting significantly up to 1 and 2 postoperative days when 
compared to the placebo. The benefit of P 6  acupressure has been 
investigated for preventing PONV in lengthy major gynaecological  
surgery lasting for up to 6 –  8 hours. Preoperatively,  a small metal bullet 
was fastened to the P 6  acupressure point  by means of an elastic bandage 
and was kept for 24 hours postoperatively and the patients were observed.  
The P6  acupressure group was observed to have significant decrease in  
nausea up to the 6
t h
 post-operative hour when compared to placebo 
group.
(3 )  
         Transcutaneous acupoint stimulation (TAES also called as the relief 
band) is a battery powered electrical device. This stimulates the P 6  point 
continuously for 6-12 hours and shows promising benefits in preventing 
post-operative nausea and vomiting as well as chemotherapy associated 
nausea and vomiting. 
(3 )  
        Acupressure at P 6  point and TAES is considered to be an effective 
alternative to conventional antiemetic therapy. However the use of 
acupressure though a promising treatment , it  is not a long lasting remedy.  
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        Lewis et al found that acupuncture did not relieve PONV associated 
with strabismus surgery in the paediatr ic group. Low frequency electrical 
stimulation is better than higher frequency in preventing PONV by 
stimulation of P 6  point.
(3 )  
 
Ginger Root (Zingiber officianale)  
For thousands of eras, herbal medications have been practiced for  
controlling nausea and vomiting. Ginger root had been found statistically 
significant in controlling post-operative nausea and vomiting in two 
double blinded placebo controlled study. Bone at al found statistically 
relevant reduction of PONV with 0.5 mg of powdered ginger root in 
capsule when compared with placebo in a response rate equivalent to 
metoclopramide 
(3 )
.  
Positive Encouragement  
Reinforcing desirable thoughts by providing positive suggestions 
are used by many people to help change undesirable behavior.  Eastern 
mystics have shown control over autonomic function such as metabolic 
rate and heart rate.  
 Two studies examined power of positive suggestion to decrease PONV.  
1)  Williams et al studied 60 women during major gynaecological  
surgery and demonstrated less nausea and vomit ing in patients who 
received positive suggestions.  
2)  Lauder et  al studied 266 patients and demonstrated that  the women 
randomized into the positive suggestion group required 16.5% less 
of antiemetics than the control group 
(3 )  
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Pharmacological Approach:  
A specific PONV antiemetic management plan can be formed by a 
complete preanaesthesia history.  Patients with obvious risks of PONV in 
terms of patient, surgery or anaesthesia should be assessed and those 
patients likely to be benefit ted from prophylactic a ntiemetics should be 
identified. Also patients in whom PONV would likely compromise patient 
safety,  delay recovery and discharge or cause a hospital admission would 
be benefitted from prophylactic antiemetic treatment. There are many high 
risks scores formulated to identify PONV
( 1 2 )
.   
Traditional antiemetic therapy :  
         Different classes of agents used for PONV includes anticholinergic,  
dopamine antagonists, antihistamines, sedatives/anxiolytics,  
phenothiazines, butyrophenones  and a combination of these drugs.  
         The reason for the availabili ty of these many agents to control  
PONV is due to the multifactorial  origin of PONV with no single 
medication being a 100% solution for all patients and for all types of 
surgery and anaesthesia. A combination therapy approach would therefore 
be more beneficial to treat a patient with difficult to treat , severe and 
persistent PONV as their multiple emetic receptors would be inhibited
(2 ,3 )
.  
Anticholinergic drugs:  
This group belongs in the oldest class of antiemetics. They inhibit  
the muscarinic and cholinergic CNS emetic receptors present in the 
cerebral cortex and pons. The action of selective muscarinic M 3  and M5  
inhibitors prevents motion sickness.  Scopolamine has an effective 
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preoperative antiemetic effect along with sedation. Atropine is not as 
potent an antiemetic as scopolamine. Both have better action against  
motion induced vomiting than motion induced nausea. Transdermal 
scopolamine is more effective against motion sickness than postoperative 
nausea and vomiting. Anticholinergics can be combined with o pioids for 
premedication for prophylactic treatment of PONV. Scopolamine prevents 
the impulses from vestibular nuclei from reaching the higher centres in 
the CNS, such as the reticular activating formation and the vomiting 
centre. It corrects the imbalance of acetylcholine and noradrenaline in the 
CNS which occurs in patients with motion sickness
(2 ,  3 )
.   
Transdermal scopolamine can prevent PONV caused by opioids (e.g.  
epidural  morphine). It  can also reduce the incidence of PONV associated 
with outpatient laparoscopy. But in order to be of benefit the patch needs 
to be applied many hours prior to induction. Transdermal  scopolamine has  
conflicting results in preventing emesis in children with strabismus 
surgery. But since opioids have longer emetogenic propert ies than the 
antiemetic properties of scopolamine , delayed post  -operative nausea and 
vomiting may occur.
 
The adverse effects of anticholinergic drugs include  sedation, dry 
mouth, blurred vision, mydriasis, dysphonia,  confusion, disorientation, 
hallucination, memory loss and urinary retention 
(2 ,3 )
.   
Phenothiazines:  
      They have a heterocyclic or aliphatic ring attached to the position 10 
of a tricyclic nucleus. They block the dopaminergic receptors in CTZ to 
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bring about the antiemetic action. They are used worldwide for their 
antiemetic action. They include promethazine, prochlorperazine,  
perphenazine, chlorpromazine,  etc.  Aliphatic phenothiazines 
(promethazine, chlorpromazine) have more of sedative rather tha n 
antiemetic potency when compared to the heterocyclic phenothiazines.  
Phenothiazines however produce adverse effects like hypotension, 
sedation, lethargy during recovery and may prolong hospital stay.  
Phenothiazines exert  a direct D 2  receptor blockade in  CTZ and have a 
moderate anticholinergic and antihistaminic action . They can tranquilize 
and sedate and are particularly effective for countering the effect of 
certain drugs on the CTZ. They are more effective in treating PONV but 
less effective to treat  motion sickness.  
Heterocycline phenothiazines are better than aliphatic 
phenothiazines in preventing PONV but they also have a higher incidence 
of extrapyramidal symptoms like:  
1)  Acute dystonia (trismus, torticollis ,  opisthotonus,  oculogyric crisis)  
2)  Tardive dyskinesia  
3)  Akathesia (motor restlessness)  
4)  Pseudoparkinsonism 
Neuroleptic malignant syndrome has been noticed as a side effect  
with phenothiazines/ droperidol and metoclopramide. It is  a syndrome 
characterized by hyperpyrexia, autonomic instability,  muscle  rigidity and 
altered mental status. Anticholinergic adverse effects of phenothiazines 
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are tachycardia, dry mouth, urinary retention,  drowsiness and hypotension 
which can be treated with IV fluids and phenylephrine 
(2 ,3 )
.  
Butyrophenones  
        Droperidol  and haloperidol have similar antiemetic effect  as 
phenothiazines. They are alpha blockers. The adverse effects include 
sedation and EPS. They act  on the area postrema and CTZ as strong D 2  
receptor antagonists. Both haloperidol and droperidol have antiemet ic 
properties but droperidol is  used more commonly in anaesthesia.  They 
have tranquilizing activity but haloperidol produces less sedation than 
prochlorperazine
(2 ,3 )
.   
Both IM droperidol 5 mg and haloperidol 2 mg have equ ipotent 
action. Haloperidol has  a faster onset of action than droperidol. But the 
duration of action is longer in droperidol and has a greater affinity for the 
D2  receptors in CTZ than haloperidol. Also when compared to 
metoclopramide 10mg, placebo and droperidol 5mg, IV droperidol 1.25mg 
administered just before the end of anaesthesia in major gynaecological  
surgeries was found to be superior. It was also found beneficial in 
elective orthopaedic surgery for female patients.  
Droperidol 5mcg /kg intravenously administered 1hour before the 
end of anaesthesia was found to be effective in children in the age group 
of 11-15 years. The i.v dose of 0.625 mg  droperidol was found to be as 
effective as i .v dose of 1.25mg droperidol  for the prevention of PONV 
when given immediately after intubation
( 3 )
.  
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Repeated and high doses of haloperidol and droperidol produce 
EPS, anxiety,  restlessness, hypotension and sedation in both elderly and 
young adults
(3 )
.  
Antihistamines:  
These include dimenhydrinate, hydroxyzine, cyclizine and 
diphenhydramine.   They bring their action by blocking:  
1)  Acetylcholine in vestibular apparatus  
2)  H1 histamine receptors of the nucleus of the solitary tract  
They are used especially in motion sickness therapy and 
prophylaxis and in controlling PONV after middle ear surgery. They can 
also be used for treating vertigo. Their side effects are sedation, blurred 
vision, dry mouth, urinary retention and delayed recovery . Cyclizine and 
hydroxyzine have sedative effects and are supplemented with opioids for 
premedication. Cyclizine has a lower incidence of side effects and is more 
effective for PONV treatment. 
(3 )
 
            Hydroxyzine is an anxiolytic medication having anticholinergic, 
antihistaminic, bronchodilatory effects in treating motion sickness, PONV 
and vertigo. It  has duration of action of 4 to 6 hours with minimal 
respiratory and circulatory depression. The antisialogogue and sedative 
action of hydroxyzine makes it suitable for being a premedication drug 
along with opioids.  
The barbiturates and opioids doses should be reduced by 50% or 
more when being given along with hydroxyzine because the CNS 
depressant effects will be highly potentiated. 100mg hydroxyzine IM 
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given after induction is more effective than droperidol  2.5mg IM in 
reducing PONV. 
(3 )  
Benzodiazepines:  
These include diazepam, lorazepam, midazolam. They have 
sedative, amnestic  and anxiolytic properties. They reduce anxiety and 
restlessness associated with anaesthesia and surgery and thereby decreases  
the incidence of PONV.  
IV Midazolam 75 mg /kg administ ered after induction prevents 
vomiting after tonsil lectomy operations in children. Lorazepam 10 mcg/kg 
compared to droperidol 75 mg/kg when given after inhalational induction 
in strabismus surgery had similar effects for controlling PONV in 
children
(3 )
.   
Benzodiazepines as such do not have any antiemetic action on any 
receptors but they reduce anxiety by decreasing catecholamines release. 
They have amnesia producing effects which prevents recall  of any 
memory of PONV. 
(2 ,  3 )  
Benzamides:  
           Metoclopramide and domperidone falls in this group with specific  
D2  (dopamine) antagonist  activity.  They are unrelated to phenothiazines 
and are lacking in antihistaminic properties. Metoclopramide is D 2  
receptor blocking agent both centrally (CTZ and area postrema) and 
peripherally (gastrointestinal tract). It is a gastrointestinal prokinetic drug 
which increases the lower oesophageal sphincter tone and increases the 
upper gastrointestinal tract motil ity. It crosses the blood brain barrier. It  
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has fewer side effects and does not affect  the anaesthesia recovery time or  
the haemodynamic stabil ity. Rapid administration may cause abdominal 
cramping.  
           Extrapyramidal tract side effects occur in less than 1 % of patients 
when treated chronically especial ly when metoclopramide 40 –  80 mg is 
used daily. It may also potentiate the CNS depr essant action of other 
drugs.  The EPS incidence caused by butyrophenones and phenothiazines 
may be enhanced by metoclopramide. This drug should be avoided in 
patients with history of seizure disorders and preexisting pyramidal 
symptoms. It  is  very beneficial and popular drug in treatment of radiation 
sickness, drug induced vomiting and migraine associated vomiting . 
Metoclopramide reverses gastric stasis induced by morphine. 
Metoclopramide 0.15 mg/kg IV given after the delivery of the baby 
reduces PONV in elective caesarean section under epidural  
anaesthesia
(2 ,3 )
.   
         After tonsil lectomy, 0.15 mg/kg IV metoclopramide given on arrival  
in the post anaesthesia care unit  prevents PONV in children. When given 
as a prophylactic antiemetic agent prior to induction there have been 
increasing doubts about it s antiemetic efficacy. This may most probably 
be due its shorter duration of action  
Domperidone is also a drug in the benzimidazole group. It is  
pharmacologically similar to metoclopramide but is similar in structure to 
haloperidol. It  acts on the CTZ against its D 2  receptor.  EPS is lower with 
domperidone as compared to metoclopramide. It cannot cross blood brain 
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barrier. It  increases the gastric emptying time due to its  prokinetic 
properties. It causes a better lower oesophageal sphincter tone  
 Domperidone is similar to metoclopramide in its effectiveness to 
prevent PONV but is superior to metoclopramide in treating PONV . The 
antiemetic treatment is dependent highly on the timing and the route of 
administration. A dose of intravenous domperidone 5 - 10 mg given in the 
recovery room can be effective in treatment of postoperative emesis.  Its  
effect is only as good as that o f placebo if given preoperatively or  
immediately after induction.  
Benzquinamide is a short acting benzoquinone derivative with 
antiemetic property due to its antiserotonin, antihistaminic and 
anticholinergic activity. It blocks these receptors in the CTZ. Sedation is 
a common adverse effect. It is effective when given intramuscularly for 
preventing and treating PONV. When administered intravenously it causes 
tachycardia, ventricular arrhythmias and hypertension
(2 ,  3 )
.  
Serotonin receptor antagonists:  
The (5 HT3) receptor antagonists are highly selective and specific 
drugs used in control of nausea and vomiting. They are also found to be 
beneficial in the treatment of radiation induced nausea and vomiting and 
also in chemotherapy induced nausea and vomiting.  
 This group includes granisetron, tropisetron, dolasetron and ondansetron.  
Role of 5HT3  receptors:  
The various agents used to prevent or treat  nausea and vomiting 
acts as dopamine, muscarini c or histaminic antagonists.  Radioligand 
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binding studies have shown a high density of 5HT3  receptors in the areas 
involved in emetic reflex. 5HT 3  receptors are present on the vagal 
terminal innervating the gastrointestinal  mucosa and in the same vagal 
afferent nerves situated at the brainstem vomiting system (i .e. the nucleus 
of the solitary tract,  dorsovagal nucleus and CTZ)
(3 )
.About 80% of 5HT 
are present in the enterochromaffin cells of the gastrointestinal mucosa. 
This is released during radiation or by cytotoxic drugs where being close 
to the vagal afferents, they activate these nerve endings and leads to 
stimulation of the emetic reflex.  Large amounts of 5HT are located in the 
gastrointestinal  mucosa at its enterochromaffin cells . It gets released due 
to radiation or cytotoxic drugs and being close to the vagal efferents, it  
can activate them to initiate the vomiting reflex.  
The action of 5HT includes provocation of pain, contraction and 
relaxation of the smooth muscle present in the blood vessels and of the 
ones present in airways and the gastrointestinal tract .  It  has got platelet 
aggregation activity and reflex actions on the heart . Serotoninergic 
pathways have been implicated for many actions in the CNS such as 
induction of sleep, influencing aggression, depression, anxiety and for 
eating behavior. They also have a role in migraine induced emesis.  
Over the past two decades, greater interest has been placed on the 
role of 5HT because of their highly selective actions on 5HT receptor 
subtypes. They are divided in 7 main groups (5HT 1  to 5HT7), the 5HT1  and 
5HT2  receptors have further subtypes.  
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Ondansetron :  this was the first of the approved drug for PONV and 
it could be administered both  intravenously and orally. They were found 
equally useful in both adults and children.  The effective dose was found 
to be 4mg given intravenously at the start  of anaesthesia or 8 mg given 
orally 1-2 hours before the induction. In children older than 2 years and 
with weight less than 40 kg, 0.1 mg/kg IV is recommended.  
Tropisetron :  It  is  a highly selective and potent 5HT 3  antagonist. It  
is also a weak 5HT4  antagonist . It  has also been tried for t he treatment of 
migraine, carcinoid syndrome and ventricular arrhythmias. Headache is 
one major side effect  while constipation, fatigue and diarrhea pose to be a 
minor side effect. Also transient variation in blood pressure has been 
reported. In most of the studies considering tropisetron for PONV 
prevention, i t  was found that tropisetron is more efficacious than placebo.   
Tropisetron 5 mg IV given as premedication is  found to be effective in 
PONV prevention after gynaecological and breast surgery. IV tropisetron 
2 mg was determined to be the optimal effective dose for treatment of 
PONV during a variety of non- abdominal and abdominal surgeries in a 
study by Alon et  al  
( 3 )
.  
         Dolasetron :  This drug gets converted to its more active form 
hydrodolasetron by the action of the plasma enzyme called carbonyl 
reductase.  This drug is 100 times more potent than ondansetron. Its  
contradiction is AV block 2 or 3 and/ or concomitant therapy with class 1 
or 3 antiarrhythmics.  For the prophylaxis and treatment of PONV 12.5 mg 
IV is used in adults which is to be given 15 to 30 minutes towards the end 
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of anaesthesia. Dolasetron given 1 –  2 hours prior to anaesthesia in 
children through oral route had similar pharmacokinetic effects as that of 
IV preparation given at induction. It  has increased clearance, with a 
shorter half-life in children when compared with healthy young adult 
volunteers.  
Nontraditional antiemetic therapy:  
Ephedrine: 
0.5 mg/ kg ephedrine given intramuscularly had similar 
effectiveness to that  of 0.04 mg/ kg of droperidol in preventing PONV 
when considering the outpatients of gynaecological laparoscopy 
procedures and i t also had significantly greater efficiency than pla cebo. It 
did not show any effect on BP nor did it have any sedative adverse 
effects. It also had similar antiemetic effectiveness in prevention of 
PONV in other laparoscopic cases with no hemodynamic variations. 
Ephedrine 0.5mg/kg given intramuscularly had  similar effectives to that 
of Propofol 0.25mg /kg given intravenously.  Intramuscular ephedrine is  
particularly useful antiemetic for PONV when it is related to orthostatic 
hypotension and or fluid dehydration.
 (3 )
 
Propofol:  
        The exact mechanism of  antiemetic activity of propofol is not 
determined. But the use of intraoperative Propofol given intravenously 
was found to be as effective as that  of intravenously given 4 mg 
Ondansetron in preventing PONV especially upto 6 hours of post-
operative period.  Subhypnotic dose of intravenous thiopentone (1 mg/kg) 
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was found to be less effective than subhypnotic doses of propofol (0.05 
mg/kg) in preventing PONV for middle ear surgery especially during the 
first 6 hours of post-operative period. Also the subhypnotic dose of 
propofol was superior in preventing PONV associated with sevoflurane 
anaesthesia than desflurane anaesthesia during outpatient laparoscopic 
cholecystectomy. The incidence of PONV had an ove rall reduction when 
0.1 ml/kg/hr infusion of i .v propofol  was used over a 20 hour 
postoperative period in comparison to  10% intralipid placebo control  
(3 )
.  
Corticosteroids:  
These were first used in preventing chemotherapy induced nausea 
and vomiting. Their effectiveness in PONV is probably associated to their 
anti-inflammatory and / or membrane stabilizing action. 1mg/kg of 
intravenous dexamethasone could be used intravenously to reduce PONV 
in children of 2 –  12 years during tonsillectomy, when administered 
before the start of surgery after mask inhalational induction (when 
compared to placebo) 
(3 )
.  
Inhaled isopropyl alcohol:  
This has been suggested as a potential antiemetic for treating 
established PONV. Merith et  al observed i nhaling isopropyl alcohol was 
as effective as other standard antiemetic drugs in rescue treatment of 
PONV
(3 )
.  
Neurokinin –  1 antagonists:  
These are unique compounds .They include CP - 122, 21; L –  
754030, GR –  205171, MK –  869, CJ11, 974.  
50 
 
Their mechanism of action seems to be associated to the inhibition  
of substance P in emesis associated regions in brainstem. They are 
particularly helpful in treatment of delayed emesis associated with cancer 
therapy, lower abdominal procedures and major gynaecological  
procedures
(3 )
.     
PHARMACOLOGY OF THE DRUGS IN THE STUDY 
PHARMACOLOGY OF METOCLOPRAMIDE
(1 3 ,1 4 )  
Metoclopramide:  
This drug was introduced in the early 1970 as a gastric hurrying 
drug and is now used worldwide as an antiemetic drug. It is a 
dopaminergic receptor antagonist and is also a prokinetic drug.  
Metoclopramide hydrochloride is a crystalline and white substance. 
It  is  odourless and freely soluble in water. Chemically it is known as 4 -
amino-5-chloro-N-[2-(diethylamino)ethyl] -2-methoxy benzamide 
monohydrochloride monohydrate and has the following str uctural formula:  
 
 
 
 
Fig.1 –  Structure of Metoclopramide  
It  has a pH of 2.5 –  6.5 for IV or IM injection and has a molecular 
weight of 354.3. Metoclopramide hydrochloride 10.5 is equivalent to 10 
mg anhydrous substance and 8.9 mg of anhydrous base.  It is water 
soluble.  
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Presentation :  It  is  available as a clear, colourless solution in 1 ml 
ampoule containing 5 mg/ml of Metoclopramide hydrochloride. It is also 
available as 10 mg tablets 15/30 mg slow release capsules and as a syrup 
containing 1 mg/ml.  
Mechanism of action :  Metoclopramide is a prokinetic drug. 
Metoclopramide sensitizes tissues to the action of acetylcholine.  It  
increases the gastric emptying and intestinal transits by increasing the 
tone and amplitude of gastric contraction . It also increases the peristalsis 
in the duodenum and jejunum and at the same time relaxes  the pyloric 
sphincter. The lower oesophageal sphincter pressure is increased due to 
its actions. There is also a direct action on smooth muscle to increase its  
tone.  
The drug’s antiemetic effects are due to peripheral and central  
dopaminergic (D2) blockade. This increases the vomiting threshold at  
CTZ. It also decreases the sensitivity of the visceral afferents which 
supply information to vomiting centre.  
The onset of pharmacological action with intravenous 
administration takes 1 –  3 minutes and with intramuscular action it  takes 
10 –  15 minutes while it  takes 30 –  60 minutes after oral administration.  
Pharmacokinetics:  
Absorption :  it  has a rapid and almost complete absorption from the gut.  
However it undergoes hepatic first pass metabolism and has a wide range 
of bioavailabil ity of 32 –  97%. 
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Distribution :  It  has a large volume of distribution of about 2.2 –  3.5 L/kg. 
Metoclopramide is 13 –  22% protein bound.  
Metabolism :  It  is metabolized primarily i n the liver. The major metabolite  
is a sulphate derivative.  
Excretion :  80% of the drug gets excreted in urine within 24 hours. 20% of 
the drug remains unchanged and the remainder is  conjugated as sulphate 
and glucuronide metabolite. It has an elimination half-life of 2.6 –  5 hours 
with a clearance of 8.8 –  11.6 ml/min/kg. Renal impairment affects the 
clearance of Metoclopramide as shown in a study of patients with varying 
degrees of renal impairment where a reduction in c reatinine clearance was 
correlated with a reduction in plasma clearance, renal clearance, non -renal 
clearance and increase in elimination half-l ife.   
Pharmacodynamics:  
CVS:  it  causes occasional hypotension during general  anaesthesia, 
dysrhythmias, cardiac arrest and hypertension in patients with 
pheochromocytoma.  
CNS :  it  raises the vomiting threshold at  CTZ. It has neuroleptic effects 
including antipsychotic action due to its  central dopaminergic antagonist  
action.          
Alimentary System :  
It  increases the lower oesophageal  sphincter pressure to almost 17 
mmHg and increases gastric  emptying t ime and gastric contractions. It 
also increases the small intestinal  transit time. It has no effect on gastric 
secretion.  
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Genitourinary System :  The drug increases ureteric peristaltic  activity.   
Metabolic effects :  Metoclopramide increases prolactin release and 
transiently increases aldosterone secretion.  
Uses: 
1)  Nausea and vomiting induced by general anaesthetic agents,  
cytotoxic agents and radiotherapy or b y biliary and hepatic 
disorders.  
2)  In digestive disorders like hiatus hernia, reflux oesophagitis and 
gastritis.  
3)  Diagnostic radiological examination of gastrointestinal system to 
increase the gastric emptying where delayed emptying interferes 
with radiological examination of gastrointestinal  system.  
4)  Migraine  
5)  Post-operative gastric hypotonia  
Adverse Effects :  
  It  can cause extra pyramidal side effects like tardive dyskinesia,  
acute dystonic reactions.  The extrapyramidal effects occur  more 
often with higher doses in elderly and in people with renal failure.  
  It  can also cause neuroleptic malignant syndrome.  
  It  can also cause Parkinsonism like symptoms.  
  It  also increases prolactin secretion.  
  Dizziness, headache, drowsiness, bowel upset, urinary incontinence 
is common.  
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  Depression, hypertension, hypersensitivity reactions and blood 
disorders are common side effects.  
Contraindications:  
1)  Metoclopramide is not to be used in conditions where stimulation of 
gastrointestinal motili ty can be dangerous, such as in mechanical 
obstruction, gastrointestinal hemorrhage or perforation.  
2)  It  should not be used in patients with pheochromocytoma also 
because the drug can cause a hypertensive crisis , by the release of 
catecholamines from the tumor.  
3)  It  is  contraindicated in subjects with known sensitivity to the drug.  
4)  It  should not be used in epileptics and patients receiving other 
drugs which can cause extrapyramidal reactions, because the 
severity of the extrapyramidal reactions can get increas ed.  
Routes of Administration/Dosage :  
      Metoclopramide can be given orally,  intravenously or 
intramuscularly.  By all routes the dosage is 10 mg 8 hourly. A dose of 1 –  
2 mg/kg is used in cisplatin associated nausea and vomiting.  
PHARMACOLOGY OF RANITIDINE
(1 3 ,1 4 )
 
       Ranitidine is a H2 (Histamine) Receptor blocker, which is chemically 
N[2-[[[5-[(dimethylamino)methyl] -2-furanyl]methyl]thio]ethyl] -N'-
methyl-2-nitro-1,1-ethenediamine, HCl.  It  has the following structure:  
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Fig.2 - Structure of  Ranitidine 
The empirical formula is C13H22N4O3S·HCl, having a molecular 
weight of 350.87.  
It  appears as a white to pale yellow, granular substance and is 
soluble in water.  It  has a sulphur like odour and has a bitter taste.   
Mechanism of action :   
Ranitidine acts  as a competitive histaminergic H 2  receptor blocker 
which blocks histamine action necessary to bring about the action of 
gastrin and acetylcholine in the gastric parietal cell .  
Presentation: 
It is present as a clear solution for IM or IV injection containing 25 
mg/ml. 150/300 mg tablets are also available. A syrup of 15 mg/ml is also 
available.   
Pharmacokinetics:  
Absorption :  Ranitidine Tablets have 50% absorption after oral  
administration compared to an IV injection with mean peak levels of 440 
to 545 kg/ml. Food and antacids do not al ter absorption.  
Distribution :  It  has a volume of distribution of about 1.4 L/kg. 15% of the 
drug is protein bound.  
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Metabolism :   It  is  metabolized in liver by oxidation and methylation. 
Liver dysfunction does not significantly affect  Ranitidine half-life,  
distribution,  clearance and bioavailability.   
Excretion :  The principle route of excretion is urine.  It has a clearance of 
10 ml/min/kg and has an elimination half-life of 1.6 –  2.5 hours. In a 
study, four patients with clinically significant renal dysfunction 
administered IV Ranitidine 5 mg showed a plasma half-life of 4- hours 
with a clearance of 29 ml/min and a volume of distribution of 1.76 L/kg.  
Pharmacodynamics:  
The drug’s major action is in the al imentary system where it has an 
anti-secretory action and reduces the gastric acid secretion, its volume, 
and also reduces hydrogen ion and total pepsin content.  
They have no action in the cardiovascular or respiratory centre. The 
drug does not have any anti-dopaminergic or anti -androgenic actions that 
are associated with cimetidine. The drug crosses the placenta but no 
adverse effect on fetal well-being is noticed.    
Uses :  
1)  Reflux oesophagitis  
2)  Zollinger –  Ellison Syndrome 
3)  Peptic ulcer disease  
4)  In critically ill  patients to prevent stress ulceration  
5)  Prior to general  anaesthesia to reduce the risk of acid aspiration  
Contraindications:  
      It  is  contraindicated in patients with hypersensitivity to the drug.  
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Adverse Reactions :  
       The adverse reactions associated with Ranitidine are rare 
manifestations in the following systems.  
CNS: Rarely malaise, dizziness, insomnia, vertigo, somnolence, mental  
confusion/ depression/ hallucinations are  seen in severely ill  elderly 
patients.  Blurring of vision and rare involuntary motor disturbances are 
seen.  
Cardiovascular:  they can rarely cause arrhythmias.  
Gastrointestinal: Constipation/ diarrhea, abdominal discomfort/ pain, rare 
reports of pancreatitis  
Hepatic:  Rarely,  they can cause alte ration of liver function tests  
Hematologic: Thrombocytopenia, leucopenia and granulocytopenia are 
seen in few patients.  
Endocrine: No significant endocrine activity is induced by ranitidine . 
Cases of galactorrhoea and gynaecomastia have been reported both  in 
males and females.  Anaphylactoid reactions may occur  
Respiratory: In a large epidemiological  study, there has been shown an 
increased risk for development of pneumonia in H 2  –  receptor blockers 
with a relative risk of 1.63,  however no causal relationship has been 
established.  
Routes of administration/ dosage:  
     Ranitidine may be administered as slow IV or IM, with dose being 
50 mg 6 –  8 hourly.  Oral dose of 150 mg twice daily can be given.  
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PHARMACOLOGY OF ONDANSETRON
(1 3 ,1 4 )  
 
 
 
 
 
 
Fig.3 –  Structure of Ondansetron  
Ondansetron is a selective 5 - HT3  blocker. 5 - HT3  is present in 
high density in the area postrema and in the nucleus tractus solitarius.   
Chemically it is  1,  2, 3, 9 -tetrahydro-9-methyl-3-[(2-methyl-1 H-
imidazol- 1-yl) methyl]-4H-carbazol-4-one. The structural  formula is  
C18H19N3O is the molecular formula and it has a molecular weight of 
293.4.Intravenous drug contains an isotonic aqueous solution which 
contains ondansetron hydrochloride dehydrate 2mg /ml.  It  has a pH of 
3.5.It contains citric acid monohydrate and a sodium citrate and has a 
shelf life of 3 years  
Presentation:  
 It  is present as a colourless, clear solution in 2/4 ml ampoules 
which contains 2 mg/ml ondansetron hydrochloride dihydrate. It is also 
present as 4/8 mg tablets.  
Mechanism of action:  
Ondansetron is a highly selective antagonist  of 5HT 3  receptor.  It 
has both central and peripheral  action. On having emetogenic stimuli 5 –
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HT3  is released in the small intestine from the enterochromaffin cells  
which brings about the vomiting reflex by action of vagal afferents via the 
5- HT3   receptors. Ondansetron blocks this reflex. Vagal afferents may 
also cause release of 5- HT3  in area postrema.   
Pharmacokinetics: -  
Absorption: 
Ondansetron can be absorbed well from the gut. It has a 
bioavailability of 56 -60%.Bioavailabil ity is slightly enhanced in the 
presence of food but not by antacids.  
Distribution:  
The drug is 70 –  76% protein bound. The volume of distribution is 
about 2L/kg.  
Metabolism:    
The drug is metabolized in the liver by either hydroxylation or by 
N–  demethylation of the indole ring and is followed by conjugation with 
glucuronic acid or sulphate.  
Excretion:  
Less than 5% is excreted in the urine unchanged. The clearance of 
the drug is 6.3 ml/min/kg. The elimination half-life is  3 hours.  However 
there is reduction of clearance and increased elimination half-l ife in the 
elderly but no dose adjustment  is recommended for the elderly.  In hepatic 
impairment, the clearance is reduced 2 fold and the half-life is increased 
to 11.6 hours.  Therefore, the dose should be limited to 8 mg/day. There is  
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no requirement for dose adjustment in renal impairment. Clearance is also 
increased in children.  
Pharmacodynamics:  
CVS:  The drug has no effect on the cardiovascular systems.  
RS:  The drug does not have any effect on the venti lat ion.  
CNS: Ondansetron is free of sedative side effects on the CNS and does not 
impair performance of psychomotor tests.  
GI System: The drug has no antimotility activity in the ga stric system, but 
it  increases the large bowel transit time.  
Uses of Ondansetron:  
1)  McKenzie R et al  in 1993 have established ondansetron as effective 
antiemetic for preventing PONV or treating established PONV.  
2)  In chemotherapy induced nausea and vomiting. The 
chemotherapeutic agents cause nausea and vomiting which is 
especially high with cisplatin therapy. Ondansetron is particularly 
effective and can be used as 8 mg and up to 10 mg in treating 
chemotherapy induced nausea and vomiting.  Studies have shown 
improved effectiveness with addition of 20mg IV dexamethasone.  
3)  Radiotherapy: In radiotherapy, irradiation of the entire body, in 
particular the upper abdomen is a cause of emesis.   Ondansetron 
8mg is efficient in  reducing emesis in such scenarios.  
4)  Use in Anaesthesia:  Several studies compared Ondansetron with 
placebo in patients undergoing surgery and anaesthesia and showed 
that ondansetron group suffered less PONV compared to placebo 
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group .The recommended dose fo r preventing PONV is 8 mg orally 
one hour prior to surgery. This can be followed by 2 doses of 8 mg 
at 8 hourly intervals.   
 Contraindications  
The use of apomorphine with ondansetron is contraindicated as this 
combination can cause profound hypotension and loss of consciousness. It 
is also contraindicated for patients known to have hypersensitivity to the 
drug.  
Side Effects:  
      Ondansetron is a well-tolerated drug with only mild and transient 
adverse reactions which includes headache, dizziness,  abdominal 
discomfort and constipation. Rarely,  ondansetron may cause 
hypersensitivity reactions. Only one study reported the incidence of 
gastrointestinal stasis.  Disturbances in liver functions as seen by ele vated 
liver enzymes have been reported. These disturbances are however self-
limiting.  Ondansetron may lead to an increase in arterial pressure with a 
reflex decrease in heart rate. But however studies have shown that there 
are no significant changes in the heart rate or in the systolic or diastolic 
pressure. There is no effect on ventilation frequency or oxygen saturation.  
There is no impairment of psychomotor function. It has no antagonism of 
dopamine receptors and therefore is  free from the extrapyramidal 
symptoms caused by metoclopramide.  
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Routes of administration.  
It  can be given as 8 mg orally at  8 hourly intervals or as a single 
dose of 4 mg intramuscularly or intravenously.  
Review of Clinical Studies:  
  The ever required need to understand,  prevent and treat PONV is 
reflected by the presence of a large number of literature s on PONV. At 
least 2000 randomized controlled trials are published to date  and almost   
200 new studies are being published every year
(1 2 )
.  
In recent large studies the inci dence of PONV is (20-
30)%
(2 ,3 )
.While in laparoscopic procedures the incidence is (53 -72%)
(4 )
. In 
a study
(1 5 )
 which collected and analyzed data over a period of three years 
to evaluate the incidence and severity of anaesthetic complications 
following pediatric  ambulatory surgery in 4998 patients i t  was reported 
that 33% of overnight admissions were due to PONV.  Many drugs are 
hence frequently studied and reported.  
In a systematic review and meta -analysis conducted by Mishriky et  
al
(1 6 )
 metoclopramide was studied for i ts efficacy and prophylaxis in 
nausea and vomiting during and after caesarean del ivery.  They conducted 
a literature search of Cochrane C entral Register of Controlled Trials , 
MEDLINE (1966-2011), EMBASE (1947-2011), CINAHL and Google 
scholar and studied RCTs which compared metoclopramide to placebo , 
used in women having caesarean delivery under neuraxial aneasthesia.11 
studies involving 702 patients were studied.  Administration of 10mg 
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metoclopramide resulted in significant reduction of intrao perative nausea 
and vomiting and also early PONV. EPS were not reported in any patients.  
De Oliveira
(1 7 )
 et al did another meta-analysis to prove the efficacy 
of metoclopramide to prevent PONV following general anaesthesia. This 
study questioned the earlie r study by Yoshitaka  Fuji
(3 7 )
 which had 
reported that 10mg systemic metoclopramide is not effective to prevent 
PONV in patients undergoing general anaesthesia.  A worldwide search for 
RCT which evaluated the use of 10mg metoclopramide for PONV was 
carried out and 30 trials involving 3328 subjects were evaluated.  They 
proved that metoclopramide reduced the incidence of PONV over 24 hours 
when compared with control , with an odds ratio of 0.58 and number 
needed to treat 78. When considered as separate outcome metoclopramide 
reduced the 24 hour nausea (with OR of 0.51 and number needed to treat  
=7.1) and also 24hour vomiting (with OR of 0.51 and number needed to 
treat  =83).They concluded that 10mg metoclopramide is efficient in 
controlling PONV. 
Metoclopramide has been used for almost 50 years to prevent 
PONV. In a quantitative systemic review of rando mized placebo 
controlled study Henzi et al 
(1 8 )
 s tudied the use of metoclopramid e in the 
prevention of PONV. They analyzed the data found in 66 studies with 
3260 patients receiving 18 different regimes of metoclopr amide and 3006 
controls receiving placebo or no treatment.  The best documented regimen 
was 10mg I.V. while in children the  best documented regimen was 
0.25mg/kg. Relevant end points studied  were prevention of early PONV(6 
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Hours post- surgery)  and late PONV (48 hours post  -surgery) and adverse 
effects . The study concluded that there was no significant anti -nausea 
effect. The numbers needed to treat and prevent early vomiting was  5.8 
(3.9-11).The drug did not have late anti -vomiting effect.  Only one patient 
experienced extrapyramidal symptoms with metoclopramide.  
William Pond
(1 9 )
 in a short study consisting of 50 ASA 1 and 2 
women undergoing laparoscopic procedures anal yzed the commonly 
ordered combination of ranitidine and metoclopramide which is given as 
premedication. The study was conducted to analyz e the effect of this 
combination on gastric volume and pH. Here they administered Tab 
Ranitidine 150mg and Tab metoclopramide 10mg before the night of the 
surgery.  Though the study was init ial ly conducted to study only the effect  
of ranitidine and metoclopramide on the gastric pH and volume, the study 
found an interesting f inding that this combination led to not only minimal 
degree of post -anaesthetic nausea (On an average of less than  1 in a scale 
of 1 to 10),  but also the vomiting incidence was  reduced.  However they 
suggested that this may be due to a central antiemetic  action of 
metoclopramide and, or  a very low gastric volume.  They suggested that a 
larger study would be necessary to produce a statistically significant 
result  to prove the validity of the finding.   
In another study conducted by Manchikanti et al
(2 0 )
 as early as  
1984, they studied ranitidine and metoclopramide and its  prophylactic 
effect on aspiration pneumonitis  in elective surgery.  They compared 10 
groups consisting of 15 subjects each. Groups 1 were taken as controls 
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while the rest 9 groups were allotted in various regimes consist ing of 
either ranitidine or  metoclopramide alone or in combination.  They found 
out that ranitidine and metoclopramide independently or in combination 
reduced the rate of aspirat ion pneumonitis  but however no association was 
brought about to the effect of drug regimes in  prevention of PONV. 
In a comparison study conducted by Cozanitis D et al 
(2 1 )
 the effect 
of ranitidine, droperidol or placebo in the prevention of nausea and 
vomiting after hysterectomy was studied.  In this study 3 groups consisting 
of 60 patients were studied in a double blinded randomized manner.  In the 
group 1, tab ranitidine was given the night before and also in the 
following morning one hour before the induction of anaesthe sia. Thirty 
minutes before surgery ended they were given 0.3ml I.V. isotonic saline. 
The second group had placebo instead of ranitidine while before the end 
of operation, droperidol  0.75mg was given. The third group received only 
the placebo rather than the study drugs both prior to induction and before 
the end of surgery. The patients were monitored in the immediate 
postoperative period (2hours) in the recovery room and they were 
evaluated in the ward until the next morning. The results showed that the 
patients who received antiemetics had less of PONV as compared to those 
who didn’t. With recovery room P=0.0109 and ward P=0.007 ,  droperidol 
had a better effect on PONV in the recovery room  (P=0.005) and there 
was no statistical significance with placebo a nd ranitidine. In the ward 
both the drugs were more effective than placebo (ranitidine P=0.01 and 
droperidol P=0.003).Rescue drug requirement was not significant in any 
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group.  And in conclusion they had reported that both the antiemetics lead 
to a decrease in PONV in comparison to the placebo.  However droperidol 
was superior to ranit idine during the immediate postoperative period.  
The study by Doenicke Aw et  al 
(2 2 )  
analyzed premedication by H1  
and H2  blockers to reduce the incidence of PONV.  The background to do 
this study was the ever existing controversy whether  the pretreatment with 
H1  and H2  had any effect in the incidence of PONV.  They did a 
randomized prospective placebo controlled clinical study in 1194 patients 
undergoing surgery.  The patients were assigned into the treatment group 
and the control group.  Group 1 (n=335) received 0.1mg/kg dimentidine 
I.V plus 5mg/kg cimetidine I.V. ,group II  (n=337) received 1.25mg/kg 
ranitidine plus 0.1mg/kg dimentidine I.V. Group III (n=316) received 
300mg ranit idine per orally plus  0.1mg /kg dimentidine I.V. Group I.V 
was control  group (n<=316) received 20ml sa line I.V. Groups I, II, III  were 
taken up for regional or general anaesthesia and group IV was taken  for 
general anaesthesia.  The incidence of PONV was 8.5%, 6.8% and 5.4% in 
groups I, II and III  who had general anaesthesia.  In patients who had 
regional anaesthesia (n=443) the incidence of nausea and vomiting was 
2.5% and 1.1% respectively.  However in control  levels (n=161) the 
incidence was 28.3% for nausea and 27.5% for vomiting. They concluded 
that premedication with H 1  and H2  blocking agents significantly reduced 
the incidence of PONV.  
Nozaki et al
(2 3 )
 also did a study to evaluate if preoperative 
administration of H2  blockers could reduce the incidence of postoperative 
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nausea and vomiting. They studied 80 patients undergoing elective 
surgeries who were randomly assigned into 2 groups with one group being 
the control  C and the other F ,who were given the H2  blocker famotidine 
20mg I.V, 20 minutes prior to induction of general anaesthesia.  The 
frequency and extent of vomiting was  observed by monitoring and 
interviewing the patients at 0 -6 and 6-12 hours. They found the 
preoperative administration of H 2  blockers tend to reduce PONV in 
women. 
Dinesh Thakur et al
(2 4 )
 did a study on  using  the combination of 
metoclopramide and glycopyrrolate on patients undergoin g cesarean 
section under spinal anaesthesia .  Their objective was to  study the 
combined effect of two frequently used traditional antiemetic drugs 
(metoclopramide and glycopyrrolate) and to compare it against published 
data of efficacy of single antiemetic drug usage  in prevention of PONV in 
women undergoing caesarean section under spinal anaesthesia. They took 
seventy eight full term parturient women posted for cesarean section 
under spinal anaesthesia for their study.  Metoclopramide 10mg & 
glycopyrrolate 0.2mg was given intravenously at the time of abdominal 
incision. The frequency of nausea and vomiting were noted. They found 
3.84% incidence of nausea during operative and postoperative period.  
There was no incidence of vomiting. No adverse effects were observed 
during the study. They concluded that incidence of vomiting was lo w 
(zero case) in their study group and then they compared their  data to other 
groups, for which the data was taken from other published research which 
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considered either  metoclopramide, glycopyrrolate or ondansetron.  They 
found that the differences were statist ically insignificant between the 
groups, but  however there was upper class interval limit  of Z value 
falling above the level of significance (>1.96) in all  groups  which 
suggested that it  might be significant and there is the need of further 
studies to prove or disprove significantly lower incidences of nausea and 
vomiting when combination  of two drugs  (glycopyrrolate plus 
metoclopramide) was used as  the prophylactic antiemetic in elective 
cesarean section under spinal anaesthesia . 
In a study by Leeser et al
(2 5 )
 the 5HT3  antagonists were analyzed in 
a randomized double blind placebo controlled study where 84 patients 
undergoing gynaecological operations under general anaesthesia were 
considered. Equal number pat ients in each group received either 16mg 
oral ondansetron or placebo.  During the first hour after recovery the 
group given placebo had 52% and 40% of nausea and vomiting 
respectively and in the ondansetron group nausea and vomiting was 17% 
and 12% respectively.  After 24hours, incidence of nausea and vomiting 
was 67% and 60% in the placebo group while it  was only 29% and 26%in 
the ondansetron group.  They thus concluded that ondansetron is effective 
in controlling postoperative nausea and vomiting.  
In a randomized placebo controlled double blind study conducted by 
Aboulwiah et al
(2 6 )
 they evaluated the effect of ondansetron on nausea and 
vomiting during elective caesarean section under spinal anaesthesia.  They 
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concluded that the intraoperative admini stration of 4mg of ondansetron 
significantly reduced the incidence of postoperative nausea and vomiting.  
Sarkar M et al
(2 7 )
 in a comparative study analyzed the effect of a 
single dose of ondansetron to that  of a single dose of metoclopramide in 
postoperative nausea and vomiting.  They carried out a prospective 
randomized control  study in 60 ASA grade I and II patients undergoing 
obstetrical laparoscopic surgery under general anaesthesia. The patients 
were monitored over a 24 hour postoperative period with th e aim to 
investigate (1) the nausea and vomiting incidence, (2) efficacy of a single 
dose of ondansetron 4mgI.V. to a single dose of metoclopramide 10mg 
I.V. and (3) their side effects. The early antiemetic efficacy after 1,4,12 
hours was 3.66,10 and 3.33%. respectively in the ondansetron group.  
There was no further vomiting after 24 hours.  While the abolishing of  
vomiting after 1,4,12 and 24 hours was 20,20,16.66 and 3.33% 
respectively in the metoclopramide group when compared to the placebo 
group (P<0.001) .Their overall conclusion was ondansetron was  a more 
effective antiemetic than metoclopramide.  
Polati et al
(2 8 )
 studied ondansetron versus metoclopramide in 
controlling PONV. They studied 175 patients with PONV during recovery 
period from anaesthesia for laparoscopic procedure.  The groups consisted 
of patients given ondansetron 4mg (58 patients) and placebo (60 
patients).The abolishing of vomiting within 10 minutes and nausea within 
30 minutes from the administration of study drugs with no further 
vomiting and nausea episodes during the first hour was obtained  in 93.1% 
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of ondansetron group,  67.1% of metoclopramide group and 35% of 
placebo group.  According to the Kaplan Meir method the probability of 
reducing PONV for 48 hour was 0.59  (95% confidence in terval 0.45-0.71) 
in the ondansetron, 0.45 (0.29-0.60) in the metoclopramide group and  
0.33(0.15-0.53) in the placebo group(P=0.003).They concluded that  
ondansetron 4mg to be more effective than metoclopramide 10mg.  
Priestman et  al
(2 9 )
 compared efficacy of  ondansetron versus 
metoclopramide in the prevention of nausea and vomiting following high 
dose upper abdominal irradiation. They compared oral  ondansetron 8mg 
TDS (in 38 patients) and oral metoclopramide  10mg TDS (in 44 patients) 
in preventing nausea and vomiting after  single exposure of radiotherapy to 
the upper abdomen.  On the first post irradiation  day vomiting or retching 
was prevented in all but one patient in the ondansetr on group whereas 
metoclopramide controlled these symptoms only in 46.1%  (P<0.001). 
Similarly nausea was better controlled in Ondansetron.  In 92-100% of the 
patients ondansetron was an effective antiemetic during the five days of 
the study period.  Metoclopramide group had a range of 70% on day 1 and 
95% on day 5.  
Vishal Gupta et a l
(3 0 )  
 studied ondansetron,  granisetron and 
metoclopramide for i ts efficacy in PONV in 60  patients belonging to ASA 
1 and 2 undergoing laparoscopic cholecystectomy under general 
anaesthesia.  They were divided into 3 equal groups (n=20).Emetic 
episodes in the first  24 hours were recorded. In the early post -operative 
period of 1-12 hours patients receiving granisetron had superior effect to 
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both ondansetron and metoclopramide.  However after 12 hours emesis 
free periods were statistically insignificant between  granisetron and 
ondansetron while metoclopramide group had no antiemetic effect.  
Kaasa et al  
(3 1 )
 compared ondansetron with metoclopramide in 
controlling chemotherapy induced nausea and vomiting.  Antiemetic 
protection in 24 hours following chemotherapy wa s achieved in 65% (26 
out of 40) in the ondansetron group and only 41% (17 out of 42 patients) 
in the metoclopramide group.  
Sandhu T et al 
(3 2 )
 in a prospective double blind study of eighty 
patients, studied the effects of ondansetron and metoclopramide in 
preventing PONV after laparoscopic cholecystectomy. The patients were 
divided into groups of forty each with  one of the group randomized to 
receive 4mg ondansetron while the othe r received 10mg metoclopramide 
I.V towards the end of the surgery.  The incidence of nausea was 45% for 
metoclopramide and 20% for ondansetron in the first 24  hours and this 
was statist ically insignificant.  There was no significant statistical  
difference between the two groups for nausea during the firs t  2 and 4 
hours but was significant between the 4 and 2hours (p=0.02) . T he 
incidence of vomiting was 20% for metoclopramide and 2.5% for 
ondansetron which was statistically significant.  (p=0.02 ).  
In another study prophylactic ondansetron versus metoclopramide 
for prevention of postoperative nausea and vomiting in elective caesarean 
section under spinal  anaesthesia  was studied by Sanjul Dandona et al
(3 3 )
.  
They did a prospective, randomized, double-blind, control study of 100 
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women undergoing elective lower segment caesarean section . They were 
divided into  2 groups of 50 each with group I receiving Metoclopramide 
10 mg I.V and Group-II receiving Ondansetron 4 mg I.V. Either of the 
drug was given to the patient as per the randomization 3-5 minutes before 
subarachnoid block.  The patients were monitored for 24 hours 
postoperatively.  Nausea, retching and emesis episodes were tabulated.  The 
results indicated that both the drugs were effective in controlling th e 
incidence of nausea in 1 hour , 4 hours and 12hours. However ondansetron  
was found more effective than metoclopramide for control of nausea,  (P < 
0.05). Ondansetron was also more effective in controll ing the incidence of 
vomiting by applying (P<0.005).Two patients complained of headache,  no 
rescue medication or no treatment failure was  observed in ondansetron 
group. In metoclopramide group, two patients  complained of giddiness 
(6%) and one complained of drowsiness (3%). 
A study was conducted by Usha et  al
(3 4 )
 with the aim to 
qualitatively compare the efficacy of metoclopramide, ondansetron and 
granisetron when used alone and  when used in combination with 
dexamethasone in the prevention of postoperative nausea and vomiting in 
patients undergoing day care laparoscopic gynaecological  surgery under 
general anaesthesia.  For this study 180 adult female patients under ASA 
Grade 1 and 2 and aged 18 to 55 years were included. The study was done 
with six groups consisting of randomly selected 30 patients in each. The 
antiemetic drugs of the study were given intravenously.  Just before 
induction of general  anaesthesia , metoclopramide (10 mg), ondansetron 
73 
 
(4mg) and granisetron (3 mg) were given alone respectively in group A, B 
and C and in the group D, E and F these drugs were combined respectively 
with dexamethasone (8 mg).  It was found that metoclopramide was very 
poor because it  had only 36.7% success rate in the prevention of PONV 
and also had of higher incidence of side effects. The success rate in the 
prevention of PONV was found to be poor in o ndansetron & granisetron 
group (63.3% & 66.7% respectively). The success rate was found to be 
good (nearly three-fourth, 73.3%) considering the combination of 
metoclopramide with dexamethasone and very good when considering 
combination of ondansetron and granisetron each with dexamethasone 
(90% in both).  
A study was designed by Kulsoom Farhat et al
(3 5 )
 to compare the  
antiemetic efficacy and  relative safety  of intravenous ondansetron and 
metoclopramide for prevention of postoperative nausea and vomiting in  
adult female patients after elective laparo scopic cholecystectomy under 
general anaesthesia .This was a  prospective, randomized,  double -blinded  
placebo-controlled study . 150 adult ASA Grade I or II female patients, 
aged 18-55 years,  undergoing elective laparoscopic cholecystectomy 
under GA were included in the study. Using random numbers table the 
patients were divided into two groups. Group A (n=50) was given 
ondansetron 4 mg/2ml while group B (n=50) was given metoclopramide 10 
mg/2 ml intravenously just prior to induction of anaesthesia. Patie nts were 
monitored for the initial 24 hours after anaesthesia. Assessment of the 
presence or absence of nausea and vomiting (by simply yes or no) was 
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carried out by a resident anesthetist double blind to the study. The rescue 
antiemetic used was (cyclizine 10 mg) I/V. It  was observed that  compared 
to the metoclopramide group, the frequency of nausea and vomiting was 
clinically and statist ically lower in the ondansetron group (p=0.035). It 
was also observed that  the use of rescue antiemetic was significantly  
greater in the metoclopramide group (p=0.022).In conclusion this study 
showed that the prophylactic use of ondansetron was more effective and 
was associated with fewer side effects in comparison to metoclopramid e. 
Moreover,  the use of metoclopramide was associated with greater adverse 
effects, like dizziness and extrapyramidal symptoms.  
 Nisar et al
(3 6 )
 conducted a study to analyze the efficacy of 
ondansetron and dexamethasone in the prevention of PONV in patients 
undergoing laparoscopic cholecystectomy. T he sample size was acquired 
by purposive non probability sampling. All the patients received a 
combination of ondansetron 4mg and dexamethasone 8mg intravenously at  
the commencement of surgery as prophylactic antiemetic. Postoperatively 
the patients were monitored for  frequency of nausea and vomiting .It  was 
observed that during the postoperative period of 24 hours, 57 (85%) 
patients did not experience nausea or vomiting. 10 (15%) patients 
experienced some degree of nausea and vomiting and required the use   of 
a rescue antiemetic.  No significant adverse effects were observed. It was 
concluded that  the combination of ondansetron and dexamethasone given 
prophylactically successfully prevented nausea and vomiting during the 
postoperative period after laparosco pic cholecystectomy.  
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Fujji Y et al
(3 7 )
 compared the efficacy of granisetron, 
metoclopramide and placebo for their comparative efficacy in controlling 
PONV. Sixty patients undergoing general anaesthesia  for major 
gynecological procedures were randomly selected and divided into three 
groups of 20 each. Group I received 3mg single IV dose of granisetron, 
group II received metoclopramide 10mg and group III received placebo in 
the form of normal saline immediately after the recovery from 
anaesthesia.  The effects were assessed during the first 3 and the following 
21 hours of postoperative period with the help of a scoring system. 0 –  no 
emetic symptoms, 1- nausea and 2 –  vomiting. The mean scores for the 
first3 hours were 0.8, 0.1,  and 0.1 for placebo, metoclopramide and 
granisetron respectively and the corresponding scores in 3 –  24 hours 
duration were 0.6,  0.5 and 0.1.There was no difference in the scores 
during 0 –  3 hours but the scoring was significant dur ing the 3 –  24 hours 
postoperative period and thus they concluded granisetron to be superior to 
metoclopramide in the prevention of PONV after anaesthesia.  
Honkavaara
(3 8 )
 compared the efficacy of ondansetron  4mg and  8mg 
with placebo for controlling PONV in 75 patients undergoing middle ear 
surgery. The study was conducted in a double blinded randomized manner. 
They found that both the doses reduced PONV and also reduced the 
number of antiemetic needed per person.(droperidol : 0.72 in placebo 
group to 0.32 in both 4mg and 8mg groups).  Ondansetron did not show 
any reduction of PONV in patients with history of  motion sickness. It 
however reduced the patients suffering from PONV from 53% to 20% and 
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also reduced the requirement of rescue antiemetic from 53% to 1 7%. They 
concluded that ondansetron was an effective drug to be used in PONV and 
also concluded that 4mg ondansetron was the recommended dose as 8mg 
did not show any decrease of PONV or the need for rescue antiemetic.  
Naguib et al 
(3 9 )  
conducted a randomized double blinded study to 
compare the antiemetic efficacy of ondansetron 4mg, tropisetron 5mg and 
granisetron 3mg with that of metoclopramide 10mg and placebo .They 
considered 132 patients undergoing laparoscopic cholecystectomy. All the 
study drugs were given in IV route 10 minutes before the induction of 
anaesthesia. Direct questioning of patients was used to assess nausea and 
vomiting at 1,  4, 9, 12, 18 and 24 hours after the recovery from 
anaesthesia. The antiemetic used as rescue drug when required wa s 
metoclopramide. The percentages of emesis free patients were 65.5%, 
52%, 48%, 29.2% and 27.6% in the ondansetron, granisetron, tropisetron, 
metoclopramide and placebo groups respectively.  They concluded 
ondansetron to be a better antiemetic than metoclop ramide or placebo. 
They had longer antiemetic activity too as the rescue antiemetics when 
required were considerably after longer duration of emesis free period. 
There was no significant statistical difference between ondansetron, 
tropisetron and granisetron groups.   
Oksur et al 
(4 0 )
 also studied the PONV control after laparoscopic 
cholecystectomy where they compared metoclopramide 10mg, granisetron 
40mg; ondansetron 15mcg/kg given immediately before induction of 
anaesthesia.  The nausea and vomiting scores of the first  three hours  
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revealed that all the drugs had similar antiemetic effects. However in 4 –  
24 hour period post-operatively metoclopramide group, has shown greater 
incidence of nausea and vomiting than the other groups.  
Domino kb et al
(4 1 )
 conducted a meta-analysis for the efficacy of 
ondansetron, droperidol and metoclopramide in the prevention of post-
operative nausea and vomiting . They performed a literature search for 
RCT using MEDLINE database and manual search. A total of 58  studies 
were considered. They found that ondansetron and droperidol was more 
effective than metoclopramide. Ondansetron was found a better antiemetic 
in children but both were found equally effective in adults.
 
Chen PP
(4 2 )
 compared the effectiveness of ondansetron and 
metoclopramide in preventing PONV in 50 patients undergoing major 
gynaecological procedures .  The patients were randomized to receive 
either ondansetron 4mg or metoclopramide 10mg during closure of the 
pelvic peritoneum. The 24hour postop erative period was evaluated for 
PONV. In the first  24 hours 20% in ondansetron group and 33% in 
metoclopramide group vomited. However in the 4 –  12 hour period, 44 % 
of ondansetron and 37.5% in the metoclopramide group vomited 
respectively.  Subsequently incidence was 52 and  37.5% respectively in 
the 12-24 hour period. The highest incidence of nausea was in the first 4 
hour after surgery being 56% in ondansetron and 37.5% in the 
metoclopramide group. This decreased to 25% in both groups in the 12 -24 
hour period.   
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 However Morris RW et al
(4 3 )
 did a multi-centre international 
placebo controlled study which evaluated the effect of ondansetron 4mg 
and metoclopramide 10mg in 1044 patients undergoing major 
gynaecological procedures under general  anaesthesia and the results were 
different from the Chenn PP et al study. The pati ents were administered 
single I.V injection of the study drug prior to induction and the post -
operative nausea and vomiting were  assessed over the 24 hour post -
operative period. Patients who received ondansetron experiencing no 
emetic episodes were (44%) while with metoclopramide it was 37% and 
only 23% of no emesis was experienced in placebo group. Similarly no 
nausea experienced in the ondansetron group was 32% and no nausea in 
the metoclopramide group was 24% and placebo was 16%. Thus they 
concluded ondansetron to be more effective antiemetic drug.  
But again in a study by Monagle et al
(4 4 )
 the efficacy of 
ondansetron versus metoclopramide in preventing PONV in patients in 
undergoing gynaecological  procedures wa s analyzed. They studied 90 
patients, who were randomized to receive either ondansetron 4mg or 
metoclopramide 0.4mg /kg and the patients were assessed in the recovery 
room, the day ward and the  following day after discharge. Both emetic 
and nausea scores were same in both the groups, with ondansetron group 
having a higher post-operative scores in the day ward (p=0.001). Thus 
they concluded metoclopramide was as effective as ondansetron to control  
PONV. 
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Watts SA
(4 5 )
 in a double blinded randomized study compa red 
metoclopramide, ondansetron and cyclizine for its  efficacy in controlling 
PONV in day case laparoscopic gynaecological  procedures under general  
anaesthesia. 38 patients received no anti emetic. 166 patients were 
randomized equally to receive either metoclopramide 10mg or 
ondansetron 4mg or cyclizine 50mg imm ediately preinduction.50% of the 
patients in no antiemetic group had nausea and vomiting. While 24% in 
metoclopramide, 20% in ondansetron  and 51% in cyclizine group had 
PONV, they concluded that there was no difference in the relative 
efficacy of ondansetron 4mg and metoclopramide 10mg. 
In a study for prophylaxis for intraoperative nausea and vomiting 
during spinal anaesthesia for caesarean section ondansetron versus 
metoclopramide was studied by Garcia et al
(4 6 )
.They conducted a double 
blinded placebo controlled study of 150  ASA 1 and 2 women, divided into 
three groups of 50 each receiving placebo, metoclopramide and 
ondansetron. Nausea and vomiting occurred in 11.6%  of the total case. 
They were absent in 91.8% of ondansetron and 91.6% of metoclopramide 
group. Only 60% of the placebo group was free from nausea and vomiting . 
They concluded that both drugs had an equal efficacy.  
For the antiemetic efficacy in cardiac surgeries metoclopramide and 
ondansetron were compared by Wood Ward et al
(4 7 )
.  Ondansetron 16mg 
was administered to 115 patients and metoclopramide 15mg was given to 
101 patients 1-2 hour before surgery.  The evaluation for nausea and 
vomiting was done after extubation till  discharge from  intensive care or 
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for a period of 24 hours. Ondansetron had a higher incidence of nausea 
when compared to metoclopramide (49.6% vs 33.7% p<0.05) and vomiting 
(42.6% vs 24.8% p<0.01). There was no difference between groups in 
terms of number of patients who accepted post - operative antiemetics 
(ondansetron 43.4% and metoclopramide 32.6%). They concluded 
metoclopramide as a better agent in PONV.  
        In another study Pugh
(4 8 )
 compared prophylactic ondansetron and 
metoclopramide in preventing PONV in patients undergoing major 
neurosurgical procedures. 60 patients undergoing routine major 
neurosurgical procedures were considered in a prospective randomized 
double blind trial. The patients were randomly allocated into 2 groups and 
were given a standardized anaesthesia. Upon closing the dura mater the 
group A patients received an intravenous injection of metoclopramide 
10mg and group B received ondansetron  8 mg intravenously. The patients 
were evaluated for 48 hours of postoperative period. The postoperative 
nausea and vomiting was less in metoclopramide group than in the 
ondansetron group.  {9(30%) Vs. 17(56%) p=0.038}. They concluded with 
their study that  ondansetron was not an appropriate drug for the 
prevention of postoperative nausea and vomiting when considering 
neurosurgical population.  
Rose JB et al
(4 9 )
 studied the postoperative nausea and vomiting in 
post tonsillectomy pediatric patients in which th ey also compared the 
efficacy of ondansetron and metoclopramide in controlling PONV. They 
randomized 200 pre-adolescent children undergoing tonsillectomy and did 
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a double blinded placebo controlled prospective study and compared the 
antiemetic efficacy of one dose of metoclopramide 0.25mg/kg or  
ondansetron 0.15mg/kg given preoperatively intravenously with the two 
doses of the same drugs which was administered one hour postoperatively.  
There was significant reduction of PONV (p < 0.005 ) by two doses of 
either metoclopramide or ondansetron ( 18% and 8% ) respectively when 
compared with placebo (50%), they concluded that two doses of 
metoclopramide 0.25mg/kg intravenously was as effective as two doses of 
ondansetron (0.15mg/kg) given intravenously.   
A study by Tang et al
(5 0 )
 did an extensive research on ondansetron , 
for not just its  effectiveness as an antiemetic but also the effect of t iming 
of the drug . They also studied its cost effectiveness and cost benefit. For 
this they studied 164 women undergoing ambulatory laparoscopic 
gynaecological  procedure in a placebo controlled double blinded study.  
The subjects were divided into 4 groups.  Group A was given placebo,  
Group B was given 2mg ondansetron at the start and 2mg after  the 
surgery, Group C was given 4mg I.V before induction and Group D was 
given 4mg after the surgery.  The patients were monitored for 24 hours 
postoperatively.  Compared to ondansetron 4mg given before the 
induction, ondansetron 4mg given after the surgery was more beneficial .  
This regime has highest patient satisfaction and lowest cost effectiveness 
ratio.  Compared to placebo, ondansetron significantly reduced PONV and 
also facilitated recovery process by reducing the time of oral intake, 
ambulation and discharge readiness.  
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Launois et al
(5 1 )
 did a study comparing the cost effectiveness of 
ondansetron with that of metoclopramide when  they are used in the  
treatment of PONV  in patients undergoing elective surgery. They 
assessed intravenous ondansetron 4mg and intravenous metoclopramide 10 
mg in the treatment of PONV  in a prospective, randomized, double-
blinded, parallel -group study in 60 hospital centres in France for its  cost 
effectiveness.  746 adult patients with PONV within six hours of recovery 
from general anaesthesia were studied. The incidence of PONV and the 
medical resources used to treat it  were collected. The incremental cost -
effectiveness of ondansetron (additional cost of successful treatment) was 
the primary outcome measure. Mean cost  effectiveness of efficient PONV 
management  was calculated for both treatments.  Costs were determined 
from the hospital  perspective.  The mean cost of PONV management per 
patient was 87.98 FF for ondansetron group and 70.86 FF for the group 
with metoclopramide. It was found that  additional 17.12 FF will give each 
patient a 15.1% improved chance of successful control of nausea and 
vomiting. However this is less than the difference in the acquisition cost  
(52.11 FF) between the two groups. The mean cost effectiveness ratio was 
190.43 FF for ondansetron and 227.85 FF for  metoclopramide.  In the 
ondansetron group the cost effectiveness ratio was lower becaus e of the 
improved effectiveness. The lower cost of PONV management outweighed 
the increased drug acquisition cost.  
In 2003, an international panel consist ing of anaesthesiologists,  
surgeons and pharmacists had met to  set  guidelines in the management of 
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PONV. These guidelines were upgraded in 2006 and recently in 20 14
(5 2 )
.
 
The salient guidelines were: To identify patients at risk for PONV in adult  
and pediatric population;  approach for baseline reduction of risks for 
PONV; to identify the antiemetic with the most effective  single therapy,  
to set combination therapy regimens for PONV prophyla xis,  inclusion of 
nonpharmacologic approaches; recommend effective strategies in 
treatment of PONV when it occurs; to provide an algorithm for the 
management of individuals at higher risk for PONV and also to set up 
PONV prevention and treatment  implement ation in the clinical setting.  
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METHODLOGY 
 
The present study was conducted in the department of 
anaesthesiology of Sree Mookambika Institute of Medical sciences, 
Kulasekharam, Kanyakumari. The study was conducted after getting 
clearance from the ethical committee of Sree Mookambika Institute of 
Medical Sciences. The data was collected from 84 ASA 1 and ASA 2  
patients scheduled to undergo elective surgeries under general  
anaesthesia.  The study was conducted over a period of 1 year,  August 
2013 to 2014.  
Design of study:  
Prospective, randomized, double blinded clinical trial with both t he 
patient and the anaesthesia drug provider blinded to the study.  
Sample Size:  
The sample size of 84 was obtained by using the statistical  program 
R using 93.1% as the benefitted incidence of using ondansetron and 66.7% 
as that for metoclopramide group .
1 5  
 
The study population (n=84) was divided into two groups consisting 
of equal number.   
Group I:  This group (n=42) consisted of patients receiving  a combination 
of intravenous ranitidine 50 mg and intravenous metoclopramide 10 mg . 
Group II:  This group (n=42) consisted of patients receiving intravenous 
ondansetron 4 mg. 
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Inclusion criteria :  
1.  Consent of the patient  
2.  Patients  undergoing surgery under general anaesthesia  
3.  Age group of above 18 years and below 60 years  
4.  Patients belonging to ASA 1- ASA 2 
Exclusion criteria  
1.  Patients with hepatic,  renal, neurolog ical  and endocrine  
abnormalities  
2.  Documented hypersensitivity to any of the study drugs  
3.  Previous history of postoperative nausea and vomiting  
4.  History of motion sickness  
5.  Patients with history of vomiting or Ryle’s tube in situ in the last  
24 hours  
6.  Emergency surgeries  
7.  Full stomach 
8.  Patients with history of acid peptic diseases,  parkinsonism and 
vertigo 
9.  Patients with history of antiemetic drug intake in the last 24 hours  
10.Patients belonging to ASA 3 and ASA 4 
METHODS 
The study conducted was a prospective, randomized,  double blinded 
clinical trial.  
All patients were visited preoperatively on the night before surgery 
and a detailed history and a detailed evaluation was done. All routine 
investigations under the hospital protocol were done. The inclusion 
cri teria were met and a writt en informed consent was taken from the 
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patient. The patients were advised to remain nil per oral after midnight.  
On the morning of surgery, randomization of the patients into the 
respective groups was  done by closed envelope technique. Both the 
patient and the principle investigator were blinded to the study. The 
patient’s  baseline pulse rate and BP were recorded. An IV access using 18 
G cannula was acquired.  
The help of the anaesthesia technician was  sort in administering the 
drug half an hour prior to induction.  The patients were randomly allocated 
into group I or group II  
1.  Group I : those who received a combination of ranitidine 50 mg IV 
and metoclopramide 10 mg IV  
2.  Group II :  those who received ondansetron 4mg IV  
Just before induction, 1mg midazolam and 0.2mg of glycopyrrolate 
was given intravenously. Patient was induced with Propofol 2mg /kg IV, 
fentanyl 1 mcg/kg IV and scoline 0.5mg/kg was given.  Laryngoscopy was 
done and patient was intubated with the proper sized cuffed endotracheal 
tube. Atracurium 0.5mg/kg IV was used as the muscle relaxant.  
Anaesthesia was maintained with N20 66%, O2 33%, Isoflurane 1- 2 % 
and intermittent doses of atracurium and fentanyl were given. The intra 
operative NIBP, pulse ra te, ETCO2 and continuous ECG were  monitored. 
Duration of surgery and anaesthesia were noted. After the surgery,  the 
patient was reversed with glycopyrrolate 0.01 mg/kg and neostigmine 0.05 
mg/kg and was extubated after being fully awake.  
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Post operatively,  analgesia was maintained with diclofenac 75 mg 
IM. Post operatively all episodes of  nausea ,vomiting and retching were 
recorded by direct questioning and cross verified with the nursing care 
staff.  
 These were assessed by a scoring method.  
NAME SCORE RETCHING SCORE EMESIS SCORE 
None 0 None 0 None 0 
Mild 1 Mild 1 Mild 1 
Moderate 2 Moderate 2 Moderate 2 
Severe 3 Severe 3 Severe 3 
 
Any side effects and the use of rescue anti emetics  (ondansetron 
4mg) were also recorded.  The number of the events was  recorded in the 
initial first hour and the 24 hours post operatively .  
Statistical analysis  
The sample size was obtained using the statistical programme R 
version 3.1. The demographic data was expressed in number, percentage, 
mean and standard dev iation. Numerical data was analyzed by using R 
software. To find the statist ically significant between the groups Chi -
square,  Fisher exact test , Student t was applied. Odds ratio was applied to 
find the correlation. P value less than 0.05 (P<0.05) was considered 
statistically significant at 95% confidence interval. The statistical  
analysis was done using statist ical programme R version 3.1.Microsoft 
Excel spread sheet was used for data entry.  Microsoft Word and Excel 
were used for generating the graphs and tables.  
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RESULTS 
Table-1: Demographic data of study groups   
Demographic 
data 
Group-I Group-II 
Number Percentage 
(%) 
Number Percentage 
(%) 
Age (years)      
18-38 19  45.24 27 64.26 
39-59 20 47.62 12 28.56 
More than 59 3 7.14 3 7.14 
Gender  
Male 18 42.86 20 47.62 
Female 24 57.14 22 52.38 
Weight (Kg)  
40-60 24 57.14 27 64.28 
61-80 16 38.1 15 35.71 
Above 80 2 4.76 0 0 
 
The demographic data in terms of age , gender and weight is  
expressed in numbers and percentages.  
Considering age: in both Group I and Group II,  there were less 
number of patients under age group of above 59 years  (7.14% in each 
group). Similar number of patients was included in the group -I and group-
II.   But in Group-II (64.26%) more number of patients  were in the age 
group between 18-38 years than in Group I (45.24%).  
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Considering gender:  18 (42.86%) and 20 (47.62%) males were 
included in Group-I and Group II respectively. In Group-I, 24 (57.14%) 
and Group-II,  22 (52.38%) females were included in the study. 
Considering weight:  Most of the patients were having weight 
between 40-60kgs in both groups, with Group I having 24 (57.14%) and 
Group II having 27 (64.28%).  
The same is graphically represented as follows:  
 
Figure-4: Distribution of Sample according to group and age  
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Figure 5: Distribution of sample according to g roup and gender 
 
Figure 6: Distribution of sample according to group and weight  
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Table-2: Clinical data of study groups  
S. 
No 
Clinical 
observations  
Group-I Group-II 
Number Percentage 
(%) 
Number Percentage 
(%) 
1.  ASA Score  *  * 
  (1) 25 59.52 27 64.28 
  (2) 17 40.48 15 35.71 
2. Type of surgery     
 Head and neck 15
#  
35.71 5
 
11.90 
 Abdominal  7
 
16.67 4
 
9.52 
 ENT 3
 
7.14 7 16.67 
 OBG 2
 
4.76 5
 
11.90 
 Breast  5
 
11.90 0
 
0 
 Orthopedic 2
 
4.76 7
 
16.67 
 Laparoscopic  4
 
9.52 12
$  
28.57 
 Urology 4
 
9.52 2
 
4.76 
 
(*P<0.05 significant , for ASA score with in the groups, but not between 
the groups, 
#
P<0.05 significant , when comparing head and neck surgery 
with other surgeries within group -I,  
$
P<0.05 significant,  when comparing  
laparoscopic surgery with other surgeries within the group -II)  
 
Table-2: Most of the patients were under ASA 1 in both the groups  
with Group I having 25 (59.52%) and Group II having 27 (64.28%) 
patients.  
The same is represented  graphically as follows:  
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Figure 7: Distribution of sample according to group and ASA physical 
status 
Considering the type of surgery in Group I,  in comparison to other 
surgeries in the group most of the patients (35.71%) had undergone head 
and neck surgery, which was statistically significant.  In group-II,  in 
comparison to other surgeries most  of the patients (28.57%) underwent 
laparoscopic surgery, which was statistically significant. In group-II there 
were no breast cancer patients.  
The same is represented graphically as follows:  
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Figure 8 : Distribution of sample according to group and type of 
surgery 
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Table-3: Duration of  surgery and anaesthesia of study groups 
S. 
No 
Clinical 
parameters  
Group-I Group-II 
Number Percentage 
(%) 
Number Percentage 
(%) 
1.  Duration of 
surgery 
    
 1 hour 12 28.57 12 28.57 
 2 hours 22 52.38 21 50 
 3 hours 4 9.52 7 16.67 
 4 hours 4 9.52 2 4.76 
2. Duration of 
anaesthesia  
    
 1 hour 2 4.76 2 4.76 
 2 hours 21 50 21 50 
 3 hours 14 33.33 12 28.57 
 4 hours 4 9.52 6 14.28 
 5 hours 1 2.38 1 2.38 
Table-3: considering the duration of surgery in both groups equal 
number of patients underwent 1 hour surgery.  Less number of patients 
underwent 3 hours surgery in Group I (9.52%) when compared to Group II 
(16.67%). Less number of patients underwent 2 and 4 hours surgery in 
Group II (50% and 4.76% respectively)  when compared to Group I 
(52.38% and 9.52% respectively) which was significant when considering 
the 4 hours duration of surgery. The same is represented graphically as 
follows:  
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Figure 9: Distribution of sample according to group and 
duration of surgery  
Considering the duration of anaesthesia s imilar number of patients  
underwent 1, 2 and 5 hour duration of anaesthesia in both the groups. In 
Group I, more number of patients  (33.33%) underwent 3 hours duration of 
anaesthesia when compared to Group-II (28.57%). Group I less number of 
patients (9.52%) underwent 4 hours anaesthesia compared to Group-II 
(14.28%).  
The same is represented graphically as f ollows:  
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 Figure 10: Distribution of sample according to group and duration of anaesthesia 
Table 4: Mean and standard deviation for each factor in Group I and 
group II are given in the table below:  
Observation 
Age Weight Duration of 
Anaesthesia 
Duration of 
Surgery 
Mean SD Mean SD Mean SD Mean  SD 
Group I  39.23 12.56 61.76 10.82 130.11 51.15 105.83 49.66 
Group II  35.76 13.36 58.76 8.70 131.07 46.18 107.98 44.79 
Table 4:The mean age in the Group I was 39.23 ±12.56, in Group II it  was 
35.76±13.36.  
The mean weight in Group I  was 61.76±10.82, in Group II i t  was 
58.76±8.70.  
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The mean duration of anaesthesia in Group I was 130.11 ±51.15, while in 
Group II it  was 131.07±46.18 
The mean duration of surgery in Group I was 105.83 ±49.66, while in 
Group II it  was 107.98±44.79.  
 
 Table 5: Overall  distribution of nausea and retching and vomiting  
Observation 
Nausea Retching Vomiting 
Initial  After 24 
hours 
Initial  After 24 
hours 
Initial  After 24 
hours 
N % N % N % N % N % N % 
Present 24 28.57 9 10.71 11 13.1 3 3.57 16 19.05 5 5.95 
Absent 60 71.43 75 89.29 73 86.9 81 96.43 68 80.95 79 94.05 
 
Table 5: 28.57% patients presented with nausea in the initial hour 
which reduced to 10.71% after 24 hours. 13.1% patients presented with 
retching in the initial hour which reduced to 3.57% after 24 hours . 19.05% 
patients presented with vomiting in the init ial hour which reduced to 
5.95% after 24 hours . 
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Table 6: Correlation of various factors with frequency of vomiting, 
nausea and retching  
Factor Nausea 
initial  
Nausea 
24 hours 
Vomiting 
initial  
Vomiting 
24 hours 
Retching 
initial  
Retching 
24 hours 
Age 0.8396 0.1558 0.6719 0.5858 1.2599 0.2708 
Weight  0.7395 0.9617 0.1624 0.8059 0.311 0.5463 
Gender* 0.0281 0.174 0.0248 0.372 0.0103 0.248 
Duration of 
surgery 
0.4313 0.9534 0.99 0.8877 0.7124 0.5292 
Duration of 
anaesthesia 
0.5019 0.9733 0.8653 0.9342 0.7737 0.4566 
 
P<0.05 significant. Only gender showed to be a significant factor in 
enhancing nausea, vomiting and retching  in the initial  hour .  
 
Table-7: Comparison of frequency of nausea and retching within the 
Group-I at initial and at 24 hours 
Observation Nausea Retching 
Initial   24 hours Initial   24 hours 
Number Number  Number  Number  
Present 12 (28.57%) 4 (9.52%)
 
4 (9.52%)
 
2(4.76%) 
Absent 30 (71.43%) 38
 
(90.48%)
 
38 (90.48%)
 
40(95.24%)
 
P value 0.02* 0.01* 0.01* 0.01* 
(*P<0.05 significant , when comparing the  frequency of presence and 
absence of nausea and retching at  initial  and  at 24 hours within the group)  
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Table 7: Considering the init ial hour: 12 patients  (28.57%) had 
nausea while 30  (71.43%) people did not have nausea which was 
statistically significant . 4 (9.52%) people had retching while 38  (90.48%) 
people did not  have retching which was statistically significant.  
Considering the 24 hour period: even after 24 hours the same 
significant difference was observed.  
 
Table-8: Comparison of frequency of nausea and retching within the 
Group-I   at initial with 24 hours                                                  
Observation Nausea  
P 
value 
Retching  
P 
value 
Initial  24 hours  Initial  24 hours  
Number Number Number Number 
Present 12 
(28.57%) 
4
 
(9.52%) 0.01
#  4 
(9.52%)
 2(4.76%)
 
0.856 
Absent 30 
(71.43%) 
38
 
(90.48%) 
0.01
#  38 
(90.48%)
 40(95.24%)
 
0.567 
 
 (
#
P<0.05 significant when comparing the frequency of nausea and 
retching at  initial  with 24 hours within the group)  
Table 8: considering nausea from initial to  24 hours,  there was 
significant reduction of nausea frequency from the initial hour. Also the 
total number of people with absent nausea rose to 38 (90.48%) when 
compared to the initial 30(71.43%) which was significant.  
Considering retching from init ial to 24 hours, only 2(4.76%) had 
nausea while 40 (95.25%) did not have nausea.  
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Table-9: Comparison of frequency of nausea and retching within the 
Group-II at initial  and at 24 hours.   
 
Observation 
Nausea Retching 
Initial   24 hours  Initial   24 hours  
Number  Number  Number  Number  
Present 12 
 (28.57%) 
5  
(11.90%)
 
7  
(16.67%) 
1 
(2.38%) 
Absent 30 
 (71.43%) 
37 
 (88.09%) 
35 
(83.33%) 
41 
 (97.61%)
 
P value 0.01* 0.02* 0.01* 0.00* 
 
 (*P<0.05 significant when comparing frequency of  nausea and 
retching at initial  and at  24 hours within the Group II ) 
Table 9; considering the init ial  hour 12 (28.57%) patients were 
present with nausea and in 30 (71.43%) patients there was absence of 
nausea which was statistically significant . 
Considering retching at initial hour, 7 (16.67%) patients had 
retching while 35 (83.33%) patients did not have retching which was  
statistically significant .  
Considering the 24 hours :  37(88.09%) patients did not have nausea 
which was significant. 41 (97.61%) patients did not have retching which 
was significant .  
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Table-10: Comparison of frequency of nausea and retch ing within the 
Group-II at initial  with 24 hours 
 
Observation 
Nausea P 
value 
Retching P 
value Initial   24 hours Initial   24 hours 
Number  Number  Number  Number  
Present 12 
(28.57%) 
5
    
(11.90%) 
0.02
#  
7 
(16.67%) 
1 
 
(2.38%)
 
0.01
#  
Absent 30 
(71.43%) 
37 
(88.09%) 
0.678 35  
(83.33%) 
41 
(97.61%)
 
0.467 
 
 (
#
P<0.05 significant when comparing frequency of nausea and retching at  
initial with 24 hours within the Group-II)  
Table 10: considering the frequency of nausea from initial  to 24 
hours, the nausea frequency reduced from 12  (28.57%) in the initial to 5  
(11.90%) in the 24 hour which was significant. The retching frequency  
also decreased to 1 (2.38%) after 24 hours when compared to the initial 7  
(16.67%) which was significant .   
 
Table-11: Comparison of frequency of nausea between the group -I and 
group-II at initial and during 24 hours  
Groups Nausea 
Initial  24 hours % of reduction 
Group-I 12 4 66.66 
Group-II 12 5 58.33 
P value 0.956 0.845 0.476 
 
p>0.5 not significant when comparing nausea in Group I with 
Group II  
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Figure-11: Comparison of frequency of nausea between the Group-I 
and Group-II at initial  and 24 hours  
 
 Table 11 and Figure 11: in the init ial hour there were equal number  
12 (28.57%) of patients with nausea in both the groups. But in 24 hours 
the nausea was present in 5 patients in Group II while in Group I nausea 
was present in only 4 patients . The reduction however was not 
statistically significant  being 66.66% in Group I and 58.33% in Group II .  
Therefore neither of the group was superior to the other.  
 
 
 
 
 
 
0
2
4
6
8
10
12
Initial 24 hours
N
u
m
b
e
r 
Time 
Group I
Group II
103 
 
Table-12: Comparison of frequency of retching between the group -I 
and group-II at initial and during 24 hours  
Groups Retching 
Initial  24 hours % of 
reduction 
Group-I 4* 2 50.00 
Group-II 7 1 85.71* 
P value 0.04 0.458 0.02 
 
(*P<0.05 significant  when comparing retching in  Group-I with Group-II)  
Figure-12: Comparison of frequency of retching between the Group-I 
and Group-II at initial  and 24 hours  
 
 
Table 12 and Figure 12 : Only 4 patients had retching in Group 
I(9.52%) when compared to 7 patients in Group II (16.67%)during the 
initial hour which was significant stat istically(with p<0.05). After 24 
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hours 2(4.76%) patients in Group I and 1(2.38%) patient in Group II had 
retching which was not significant. After 24 hours 85.71%   patients had 
reduction of retching in Group II compared to 50 % in Group I which was 
statistically significant. Therefore both groups had statistically significant 
effect in controlling retching but at different time intervals, with Group I 
having more number of retch free period in the initial hour and Group II  
having better retch reduction  in 24 hours’  t ime interval. Thus both are 
efficient in controlling the retch.    
Table-13: Comparison of frequency of vomiting at  the initial hour, at 
24 hour within the Group-I 
Observation Vomiting 
Initial   24 hours 
Number Number  
Present 10 (23.80%) 2(4.76%)
 
Absent 32 (76.19%) 40 (95.24%)
 
P value 0.02* 0.01* 
 
 (*P<0.05 significant when comparing frequency of vomiting at initial,  at  
24 hours in the Group-I) 
Table 13:during the initial hour 32  (76.19%) patients had absence 
of vomiting which was statistically significant and after 24 hours 40  
(95.24%) patients had absence of vomiting which was statistically 
significant.  
 
105 
 
Table-14: Comparison of frequency of vomiting  from the initial hour 
to 24 hours within the Group-I patients  
Observation Vomiting P value 
Initial   24 hours 
Number Number  
Present 10 (23.80%) 2 (4.76%)
 
0.01
#  
Absent 32 (76.19%) 40 (95.24%)
 
0.02
#  
 
(
#
P<0.05 significant  when comparing frequency of vomiting from initial  
to 24 hours in the Group-I)  
Table 14: compared to the 10 (23.80%) patients with vomiting in 
the initial hour only 2  (4.76%) had vomiting in 24 hours which was 
statistically significant. Compared to 32 (76.19%)  in the initial hour,  40 
(95.24%) patients did not have vomiting in 24 hours which was significant 
statistically.  
Table-15: Comparison of frequency of vomiting at  initial ,  at 24 hours 
within the Group-II patients  
Observation Vomiting 
Initial   24 hours 
Number Number 
Present 6 (14.28%) 3 (7.14%)
 
Absent 36 (85.71 %) 39 (92.85%) 
P value 0.02* 0.02* 
 (*P<0.05 significant  when comparing the  frequency vomiting at initial, at  
24 hours in the Group-II)  
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Table 15: considering the initial hour 36  (85.71 %) patients did not 
have vomiting and only 6 (14.28%) patients had vomiting which was 
significant. Considering the 24 hours, 39 (92.85%) patients did not have 
vomiting and only 3 (7.14%) patients had vomiting which was significant.  
Table-16: Comparison of frequency of vomiting  from the initial  hour 
to 24 hour within the Group-II patients  
Observation Vomiting  
P value Initial  After 24 hours  
Number Number 
Present 6 (14.28%) 3 (7.14%)
 
0.789 
Absent 36 (85.71%) 39 (92.85%) 0.534 
 (P>0.05 no significance when comparing the  frequency of vomiting from 
initial to  24 hours in the group-II)  
Table 16: there was no statistically  significant reduction in 
presence of vomiting after 24 hours when compared to the initial hour.  
There was also no statistically significant increase in the frequency of 
absent vomiting after 24 hours .  
Table-17: Comparison of frequency of vomiting between the group -I 
and group-II at initial and 24 hours 
Groups Vomiting 
Initial  24 hours % of reduction 
Group-I 10 2 80.00* 
Group-II 6* 3 50.00 
P value 0.05 0.73 0.04 
 (P>0.05 not significant  when comparing frequency of vomiting in  Group-
I with Group-II at  24 hours and P<0.05 significant when comparing 
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frequency of vomiting in Group-I with Group-II in initial  hour and when 
considering the reduction of vomiting ) 
Figure-13: Comparison of frequency of vomiting between the group -I 
and group-II at initial and during 24 hours  
  
 
Table 17 and Figure 13:   In Group II only 6 (14.28%)  patients had 
vomiting when compared to the 10 (23.80%) in Group I  in the initial hour 
which was significant.  But after 24 hours Group I had only 2(4.476%) 
patients with vomiting while in Group II 3(7.14%) patients had vomiting . 
While considering the reduction , Group I reduced vomiting in 80% and 
Group II reduced in 50% which was significant.  Therefore though Group 
II significantly controlled vomiting in the initial hour , it  was Group I that  
had a significant reduction in 24 hours.       
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Table-18: Comparison of addition of other rescue antiemetic  and 
complications for the Group-I and Group-II 
Other  Group-I Group-II 
Number Percentage 
(%) 
Number Percentage 
(%) 
Rescue antiemetic  1 2.38 2 4.76 
Adverse effect  1 2.38 1 2.38 
  Table-18: In group-I only one patient had other rescue anti-emetic 
and side effect of abdominal discomfort . But in group-II,  2 patients had 
other rescue anti-emetic and 1 patient had side effect of headache but 
these were statistically insignificant  values with P>0.   
 
Table-19: Multiple comparison frequency of presence of nausea, 
vomiting and retching at different time intervals  
Groups Time period NAUSEA VOMITING RETC 
Group-I Initial  12 10 4 
Group-I  24 hours  4* 2* 2 
Group-II   Initial  12
#  
6
#  
7
#  
Group-II    24 hours  5*
, $  
3*
, $  
1
$  
(*P<0.05 significant  when comparing the  frequency of number of patients 
with nausea, vomiting and retching in group-I initial with other time 
interval, 
#
P<0.05 significant when comparing frequency of number of  
patients with nausea, vomiting and retching  in group-I  24hours with other 
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time intervals , 
$
P<0.05 significant  when comparing frequency of number 
of patients with nausea, vomiting and retching  in group-II initial with 
other time intervals) 
Table 19: when considering Group I initial:  there was significant 
reduction of nausea when compared with Group I after 24 hour and when 
compared to Group II after 24 hours.  There was significant reduction of 
vomiting when compared to Group I after 24 hours and Group II after 24 
hours.  There was no significant reduction of retching.   
When considering Group I after 24 hours: there was significant 
reduction of nausea when compared with Group II init ial .  There was 
significant reduction of vomiting when compared with Group II initial.  
There was significant reduction of retching when compared to Group II 
initial.  
When considering Group II init ial :  it  showed significant reduction 
of nausea, vomiting and retching when compared to Group II after 24 
hours  
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DISCUSSION 
PONV is one of the most dreaded complications of anaesthesia 
which is particularly high after general anaesthesia. It not only has a 
physical but also metabolic and ps ychological  effects.
(9 )  
The incidence of 
PONV still  remains high at about 20 -30 %
(2 ,3 )
.  In a study by Patel et  
al
(1 5 )
,  which considered the pediatric age group,  33% of overnight 
admissions were due to PONV. In our study however the pediatric age 
group was excluded. The incidence of nausea ranging from the  initial  first  
hour up to 24 hours was about 28.57 to 10.71 %, that of retching was 13.1 
to 3.51% and that of vomiting was 19.05 to 5.95%.  
The presence of such a high incidence is not due to the absence of  
antiemetics but due to the mult ifactorial  origin of PONV
(2 ,3 )
.  There are a 
wide range of antiemetics available for the treatment of PONV, but it  is 
constantly needed to review these drugs not just to upgrade the 
effectiveness of the drug but also to contain the cost of PONV treatment.  
PONV leads to such a distressing scenario that patients are willing to pay 
up to $100 for the effective treatment
 (1 )
.   But it  is unethical  to put such 
an additional economical  and physical strain on the patients.  Therefore it 
is required that  cost and treatment effective  drugs should be used.  
In this study metoclopramide in combination with ranitidine  was 
compared with ondansetron for its efficacy in PONV treatment occurring  
after general anaesthesia. The high incidence of PONV did not justify the 
usage of placebo in our study and was thus avoided. There are  numerous 
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factors that can influence PONV, which can be patient related  like age 
,gender ,weight ,relevant previous history of nausea and vomiting or the 
factors could be surgery related 
(2 ,3 ,7 ,1 1 )
.  In the present study many factors 
like age, weight,  duration of surgery and duration of anaesthesia showed 
no influence on the PONV incidence . However gender was found to be a 
statistically significant factor in PONV. Female gender is considered as 
an independent risk factor for PONV as shown in the simplified risk 
factors of PONV by Apfel et al
(1 2 )  
.   
The sample size of the present study was 84 which was similar to 
the sample size in the study by Leeser
(2 5 )
.  The dosage for the study drugs 
were obtained from the previous established dosages. The dose of 
metoclopramide was obtained with reference to the meta analysis by 
Henzi
(1 8 )
 in 1999, Mishriky
(1 6 )
 in 2012 and  de Oliveira
(1 7 )
 in 2012. The 
dose of ranitidine was taken from the textbook information 
(1 3 ,1 4 )
.  The 
dosage of ondansetron was taken from the study by Kaasa
(3 1 )
,  
Aboulwiah
(2 6 )
,  Launois
(5 1 )
.   Metoclopramide is a prokinetic drug 
belonging to the benzamide group
 (2 ,3 ,1 3 )
.  Ranitidine is a H2 receptor 
blocker
(1 3 ,1 4 )
.  Ondansetron is a highly selective  5HT3  receptor 
antagonist
(1 3 ,1 4 )
.  The drugs were given prior to the induction of 
anaesthesia which was similar to what was done by Oksuz
(4 0 )
,  Morris
(4 3 )
,  
Watts
(4 5 )
,  Garcia
(4 6 )
,  Nozaki
(2 3 )
,  de Oliveira
(1 7 )
.   The anaesthetic technique 
was standardized for all patients and controlled ventilation was provided. 
The data collected from the postoperative period was collected and then 
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statistically analyzed. A successful PONV treatment is considered by the 
complete control or absence of nausea, retching and vomiting. 
These drugs were chosen for the study because for over 50 years 
metoclopramide had been used in the treatment of PONV. But of recent 
their effectiveness has been overshadowed by other drugs  like 5HT3 
blockers which claim to be superior in its efficacy in the treatment of 
PONV. But in the study by Mishriky
( 1 6 )
 and Habib
(1 8 )
 in 2012,  it  was 
shown that  10 mg of metoclopramide when given did bring  in a reduction 
of PONV . In this present study too it was shown that metoclopramide did 
significantly reduce the incidence of nausea,  retching and vomiting.  In 
our study too it was found that metoclopramide wa s effective in reducing 
the incidence of PONV. In this study, nausea was absent in 90.48%, 
retching was absent in 95.24% while vomiting was absent in  95.24% of  
patients when considering the 24 hour postoperative period. However this 
result differed from the studies by Fuji
(3 7 )
 where they claimed that  
metoclopramide was an ineffective antiemetic agent .Another author de 
Oliveira
(1 7 )
 in 2012 challenged the Fuji studies  and had conducted a 
meta-analysis in which the antiemetic effect of metoclopramide was 
analyzed .The conclusion of the meta analysis was that metoclopramide 
was an effective antiemetic agent .Our st udy too had the same analysis.  
But in our study it was not just metoclopramide that was used but 
instead a combination of metoclopramide with ranitidine was considered 
in the first group. The basis of combining another drug with 
metoclopramide was on the fact that combination of drugs have better  
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chances in reduction of PONV as outlined in the guidelines of PONV 
management
(5 2 )
.  Ranitidine an H2 blocker in combination with 
metoclopramide have been studied  by William Pond 
(1 9 )  
in 1987, however 
this study was conducted with the aim of analyzing the efficacy of this 
combination in preventing aspiration pneumonitis . However during the ir 
study, the efficacy of this combination in the prevention of postoperative 
nausea and vomiting was also observed. Our study took note of this useful 
finding and reached a similar conclusion. Moreover in a study by 
Cozanit is
(2 1 )
 also, i t  was shown that ranitidine reduced PONV when 
compared to placebo . Also in the study by Doenicke
(2 2 )  
 where the effect 
of  H1 and H2 blocker’s benefit in PONV was compared to placebo it  
showed that H1 and H2 blockers reduced PONV with the incidence of 
PONV being only 8.5%, 6.8% and 5.4% with re spect to the different 
combinations of H1 and H2 blockers that  was used in the study.  Even in 
our study in the group I which contained the  H2 blocker, ranitidine the 
incidence of nausea was 9.52%, vomiting was 4.76%, and retching was 
4.76 % when considering the PONV prevalence after 24 hours.  
The second group in our study had ondansetron which is a 5HT3
 
blocker which is considered as a very efficient an tiemetic agent.   
Leeser
(2 5 )  
 did  a study in 84 patients  and divided them into  two equal 
groups containing 42 patients each and studied ondansetron against  
placebo in controlling PONV. Leeser
(2 5 )
 found the incidence of nausea and 
vomiting was 17 and 12 % in the init ial postoperative period and 29 and 
26% in the 24 hour postoperative period.  In our study too, 84 patients 
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were considered, out  of which 42 fell in the ondansetron group.  In our 
study the incidence of nausea was 28.57% in the init ial  hour and 11.90% 
after the 24 hour postoperative period and vomiting incidence was 23.80% 
in the initial  hour and 4.76% after the 24 hour postoperative period. Both 
Leeser’s and our study had the same conclusion th at ondansetron was an 
effective agent in reducing PONV. Similarly the study by Honkavaara  
showed that  ondansetron  was effective in reducing PONV from 53 to 20%. 
In our study it  was shown that  ondansetron reduced nausea from the initial  
hour 28.57% to 11.90% in the 24 hour postoperative period while retching 
was reduced from 16.67% in the init ial hour to 2.38 % in 24 hour 
postoperative period and the incidence of vomiting was  reduced from 
14.28 % in the initial hour to 7.14% in 24 hour postoperative period.  
Now coming to the comparison of the two study drug group ,  many 
studies such as that  by  Sarkar
(2 7 )
,  Polati
(2 8 )
,Vishal Gupta
( 3 0 )
,  Kaasa
(3 1 )
 
,Sandhu
(3 2 )
,  Sanjul
(3 3 )
 and Kulsoom
(3 5 )
 have concluded that  ondansetron  
was a better antiemetic agent than metoclopramide.  
However studies by Woodwand
( 4 7 )
,  Pugh
(4 8 )
 concluded 
metoclopramide to be a better agent. But the studies by Chen
(4 2 )
,  
Monagle
(4 4 )
,  Watts
(4 5 )
,  Gracia
(4 6 )
 and Rose
(4 9 )
 concluded both the drugs to 
be equally efficient.  
In our study too the findings were towards both groups of drugs 
being equally efficient in controlling PONV. The salient findings in our 
study were:   
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1.  In considering nausea in the metoclopramide group,  in the initial  
postoperative period it  was 28.57% which became 9.52% in the 24 
hour postoperative period.  In the ondansetron group too in the 
initial hour nausea was present in 28.57% which became 11.90 % in 
the 24 hour postoperative period.  
When comparing the nausea reduction in both the groups, though 
metoclopramide ranitid ine reduced nausea in 66.66% of patients and 
ondansetron reduced in only 58.33% this was not found statistically 
significant.  
2.  When considering retching, though in the initial  hour 
metoclopramide ranitidine group had retching only in 9.52% of 
patients ondansetron had retching in 16.67% patients. This however 
became irrelevant after 24 hours where ondans etron reduced 
retching in 85.71% of the group while metoclopramide could reduce 
in only 50%. 
3.  When considering vomiting, in the init ial hour ondansetron was 
found better with only 14.28 % patients having vomiting while  
metoclopramide ranitidine group had 23.80%. However after 24 
hours significant reduction was  seen in metoclopramide ranitidine 
group with a reduction of 80% when compared to ondansetron group 
which had only 50% reduction. 
In the study by Chen 
(4 2 )
in the initial hour ondansetron was  found as  
a better antiemetic with (20%) patients vomiting and in metoclopramide 
group 33% patients vomiting .  However in the 24 hour postoperative 
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period metoclopramide group had only 37.5% patients vomiting while 
ondansetron had 44 %. Monagle 
(4 4 )
 too had similar reports with both 
drugs being efficient  but with ondansetron group having more emesis after  
24 hours. In the study by Garcia 
(4 6 )  
PONV was absent in 91.8% of 
ondansetron and 91.6% of metoclopramide group and they too concluded 
both drugs were equally efficient .  
Not many studies have given enough reports on retc hing however in 
our study it was seen that only 9.52% had retching with metoclopra mide 
ranitidine ,and 16.67% had retching with ondansetron when considering 
the initial  hour  but after 24 hours the reduction seen with 
ondansetron(85.71%) was greater than the reduction seen with  
metoclopramide ranitidine (50%). Only one patient (2.38%) had to be 
given rescue anti emetic in group I while two patients (4.76%) required 
antiemetics in group II which was similar to the study by Sanjul
(3 3 )
.  
In both the groups both the drugs were well tolerated with only one 
patient complaining of abdominal discomfort in Group I and one patient 
complaining of headache in Group II.   Thus there was no statistically 
significant difference in the efficacy of the two study group.   
Adding a note on expense, Tang
(5 0 )  
in a study and Launois
(5 1 )
 in 
another study evaluated the cost effectiveness of ondansetron  where they 
both concluded that  ondansetron  was more cost  effective . In the study by  
Launois
(5 1 )
,which was conducted in France the mean cost of PONV 
treatment with ondansetron was 87.98 FF and that  of metoclopramide 
70.86 FF. But they evaluated that the higher cost of ondansetron treatment  
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could be overlooked because of the superiority of ondansetron  in 
treatment of PONV .However with reference to our  study both 
ondansetron and metoclopramide  , ranitidine were found equally efficient 
in controlling PONV . So this study conclu des that both metoclopramide-
ranitidine combination and ondansetron  can be used if cost effectiveness 
is to be considered along with effective management of PONV . 
Limitations in the study were  because of lack of adequate resources 
and time, issues such as economical impact of PONV as a whole and the 
expense imposed by the individual study drugs could  not be evaluated. 
Also follow up of variables like delay of hospital  discharge,  sequelae of  
PONV were not studied which could be considered as the shortcomings of 
our study.   
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 CONCLUSION 
 
PONV is one of the most distressing consequences following 
general anaesthesia.  Metoclopramide has been used previously for the 
treatment of PONV, but are now on a declining trend with the 
establishment of 5HT3 blockers .But metoclopramide was not only 
effective but also a cheap drug available for PONV treatment.  Therefore 
in our study we studied a combination of metoclopramide 10 mg with 
ranitidine 50 mg for comparing its efficacy with 4 mg of ondansetron 
which is considered a better antiem etic drug. Both groups were given by 
the intravenous route prior to the induction in adult patients undergoing 
general anaesthesia.  The patients were monitored postoperatively for the 
occurrence of nausea , retching and vomiting frequency which was 
recorded as that at initial first hour and that of 24 hours of postoperative 
period. It  was statistically analyz ed at the end of which we found and 
conclude that the combination of metoclopramide 10 mg and ranitidine 50 
mg given intravenously was as   efficient as ondansetron 4mg in their  
action to control PONV.    
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SUMMARY 
 
PONV is multifactorial, hence requiring multifactorial treatment 
modalities especially in patients  with high risks of developing PONV.  
After attaining the institutional ethics committee’s approval 84 patients 
under ASA 1 and 2,  in the age group of 18-60 years posted for elective 
surgeries under general anaesthesia were randomized into two equal 
groups of  42 each. Group I received a combination of metoclopramide 10 
mg and ranitidine 50 mg I.V while Group II received ondansetron 4 mg 
I.V. Both drugs were given half an hour prior to induction. 
Standardization of anaesthetic technique was done and vitals were 
monitored. Postoperatively the ep isodes of nausea ,retching and vomiting 
were monitored for 24 hours and was recorded as reading  at  initial first  
hour and at  the end of 24 hour postoperative period  .Complete response to 
antiemetic prophylaxis defined by absence of nausea, retching and 
vomiting with no need of rescue antiemetic were noted .  
The combination of metoclopramide 10 mg and ranitidine 50 mg 
was found to be as effective as 4mg ondansetron when given  prior to 
induction. There was no significant adverse effect with either study 
group.   
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APPENDIX II 
INFORMED WRITTEN CONSENT FORM 
PART 1 OF 2 
INFORMATION FOR PARTICIPANTS OF THE STUDY 
 
 
 
 
 
 
 
1. Name of the Principal Investigator :Dr. Mohsina Basheer 
  Junior Resident, 
  Department of Anaesthesiology, 
  Sree Mookambika Institute of Medical    
  Sciences, Kulasekharam. 
2. Name of the Guide   :Dr.G.Parvathy, 
                                                                          Professor, 
                                                                          Department of Anaesthesiology, 
                          Sree Mookambika Institute of Medical  
        Sciences, 
                                                                    Kulasekharam -629161. 
3. Name of Co- Guide   :Dr.V.G.Jayaprakash, 
                                                                          Professor, 
                                                                          Department of Anaesthesiology, 
                          Sree Mookambika Institute of Medical  
        Sciences, 
                                                                    Kulasekharam -629161. 
Dear Volunteers, 
 We welcome you and thank you for your keen interest in participation in this research 
project. Before you participate in this study, it is important for you to understand why this 
research is being carried out. This form will provide you all the relevant details of this research. 
It will explain the nature, the purpose, the benefits, the risks, the discomforts, the precautions 
and the information about how this project will be carried out. It is important that you read and 
understand the contents of the form carefully. This form may contain certain scientific terms 
and hence, if you have any doubts or if you want more information, you are free to ask the study 
personnel or the contact person mentioned below before you give consent and also at any time 
during the entire course of the project. 
iii 
 
4. Institute      :Sree Mookambika Institute of Medical  
 Sciences, Kulasekharam, 
 Kanyakumari District – 629161 
 Tamil Nadu. 
5. Title of the study    :  
Comparison of intravenous ranitidine and metoclopramide versus intravenous 
ondansetron in preventing post-operative nausea and vomiting post general 
anaesthesia. 
6. Background information  :  
Postoperative nausea and vomiting (PONV) remain one of the most frequently 
encountered complications of after surgeries. And this may lead to increased 
hospital stay for patients. There are many drugs available to prevent this problem. 
This study is to find out the best available drug. 
7. Aims and Objectives  :  
To compare the efficacy of ranitidine plus metaclopramide to that of 
ondansetron  in controlling  post-operative nausea vomiting in patients undergoing 
general anaesthesia. 
8. Scientific Justification of Study:  
There is a wide range of antiemetic drugs. The use of these drugs are however 
restricted by both cost and adverse effects and despite many studies, evidence 
base to support rational antiemetic treatment remains patchy. Therefore it 
becomes mandatory to frequently revive the studies to enroll the drugs with 
maximum efficacy. 
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9. Procedure for the Study :   
The patients posted under general anaesthesia are reviewed overnight and kept 
under NPO since 12 midnight. On the morning of the surgery the patients after 
meeting the inclusion criteria can be randomly selected to fall into group I or 
group II.  In each group we are required 42 patients. If the patient falls under 
group I, ranitidine 50mg and metoclopramide 10 mg is given half an hour before 
the surgery. If the patient is in group II, ondansetron 4mg will be given half an 
hour before the end of the surgery. Post operatively the patient will be monitored 
for 24 hours and the findings of which will be tabulated at 1hour and 24hour. The 
frequency of nausea, retching and vomiting will be scored as 0, 1, 2, 3 where: 
0-none, 1- mild, 2-moderate,3-severe 
10. Expected risk for the participant:  
Few people may experience the following reactions; 
a. Metoclopramide – fatigue, drowsiness, abdominal discomfort 
b. Ranitidine - pain in muscles and joints, allergy 
c. Ondansetron -  Dizziness, headache, constipation 
11. Expected benefits of research for the participant:  
The participant will contribute to medical development and can also be 
benefitted in any future surgeries. 
12. Maintenance of Confidentiality :  
All data collected for the study will be kept confidentially and would reflect 
on general statistical evaluation only and would not reveal any personal details. 
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13. Why have you been chosen to be in the study?   
 You are undergoing general anaesthesia and fulfill the criteria of selection. 
14. How many people will be in the study? : 84 
15. Agreement of compensation to the participant:  Yes.(by the investigator) 
16. Anticipated prorated payment, if any, to the participant(s) of the study:  Nil 
17. Can I withdraw from the study at any time during the study period? : Yes  
18. If there is any new findings/information, would I be informed? : Yes 
19. Expected duration of Participant’s participation in the study:  24 
hours 
20. Whom do I contact for further information?: Dr. Mohsina Basheer 
 
 
 
 
Place: Kulasekharam 
Date: 
Signature of Principal Investigator 
Signature of the Participant 
 
 
 
 
 
 
 
For any study related queries, you are free to contact 
Dr.Mohsina Basheer 
Junior Resident 
Department of Anaesthesiology 
Sree Mookambika Institute of Medical Science, Kulasekharam 
Mobile No: 9585782064 
Email ID: mohsinabasheer23@gmail.com 
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CONSENT FORM 
 
PART 2 OF 2 
 
PARTICIPANTS CONSENT FORM 
 
 
The details of the study have been explained to me in writing and the details 
have been fully explained to me. I am aware that the results of the study may not be 
directly beneficial to me but will help in the advancement of medical science. I 
confirm that I have understood the study and had the opportunity to ask questions. I 
understand that my participation in the study is voluntary and that I am free in 
withdraw at any time, without giving any reason. Without the medical care that will 
normally be provided by the hospital being affected. I agree not to restrict the use of 
any data or results that arise from this study provided such a use is only for scientific 
purpose(s). I have been given an information sheet giving details of the study. I fully 
consent to participate in the study titled “Comparison of intravenous ranitidine and 
metoclopramide versus intravenous ondansetron in preventing post-operative nausea 
and vomiting post general anaesthesia”. 
Serial No / Reference No: 
Name of the Participant :    Address of the Participant: 
 
 
Contact Number of the Participant: 
 
  Signature/ Thumb impression of the participant/ Legal guardian 
Witnesses: 
1. 
2. 
Date: 
Place: 
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APPENDIX III 
PROFORMA FOR THE STUDY 
 
Name of the patient: 
Age: 
Sex: 
IP Number: 
Surgical Diagnosis: 
Proposed Surgery: 
Relevant history: 
History of drug allergy, drug reaction, previous surgeries: 
GENERAL EXAMINATION  
Height:                                                                      Weight: 
Pallor:                  Icterus:               Cyanosis:                                    Clubbing:    
Lymphadenopathy:                            
Edema: 
Any other relevant findings: 
Pulse rate: 
Blood pressure: 
Temperature: 
SYSTEMIC EXAMINATION 
Examination of Cardiovascular system: 
 
Examination of Respiratory system: 
 
Examination of Gastrointestinal system: 
 
Examination of Central Nervous system: 
ASSESSMENT OF AIRWAY 
Mallampati grade: 
Thyro-mental distance: 
Mouth opening distance: 
Neck – range of motion: 
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Teeth: 
Facial hair: 
Morbid obesity: 
Short muscular neck: 
Micrognathia: 
INVESTIGATIONS                               
Haematological: 
  Haemoglobin, total count, differential count, ESR 
  Bleeding time, clotting time 
  Blood sugar 
  Blood urea, Serum creatinine 
  HIV, HBsAg 
Urine examination for sugar, albumin and microscopy 
ECG 
Chest X-ray- PA view if needed. 
ASA physical status 
Premedication: 
Intra-operative monitoring: pulse rate, blood pressure, peripheral oxygen saturation, 
end tidal carbon dioxide. 
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APPENDIX IV 
CASE RECORD FORM 
 
STUDY GROUP: 
Name of the patient:    Age:  Sex:  Weight 
IP Number:  ASA:   Type of Surgery:  
 
Relevant history Yes No Specify 
 Previous History of nausea, vomiting and 
motion sickness. 
 Drug Intake 
 Drug allergy 
 Drug reaction 
 Previous surgeries 
 Co-morbidities 
 Others 
   
Duration of Anaesthesia : 
Duration of Surgery  : 
 Drugs Dose 
Induction Agent   
Other drugs used   
Maintenance   
Intraoperative Monitoring 
TIME SPO2 HR BP MAP ETCO2 TV 
       
       
       
       
       
       
x 
 
Post-Operative Monitoring: Initial Hour 
OBSERVATION NAUSEA RETCHING VOMITING 
None    
Mild    
Moderate    
Severe    
Post-operative monitoring during 24 hours 
OBSERVATION NAUSEA RETCHING VOMITING 
None    
Mild    
Moderate    
Severe    
Use of rescue antiemetic 
Observation Initial hour  During 24 Hours 
Present   
Absent   
Adverse Effect 
 Absent: 
 Present: 
Specify: 
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APPENDIX V 
 
KEY TO THE MASTER CHART AND MASTER CHART 
 
 
1. S. No     - Serial number 
2. IP no     - In patient number 
3. ARM     - Group, where 
       1=Group I 
       2=Group II 
4. NAME    - Name of the patient 
5. AGE      - Age of the patient 
6. SEX     - Gender, where 
       F= Female 
       M=Male 
7. Wt     - Weight of the patient 
8. ASA      - American Society of Anaesthesiologists,
       where  
       1= ASA 1 
       2 = ASA 2 
9. SURGERY     - Type of surgery, where  
Head and neck - Surgeries involving the head and neck 
Abdominal   - Abdominal surgeries 
ENT   - Ear, nose and throat surgeries 
OBG   - Obstetrics and gynaecological surgeries 
BREAST  - Breast surgeries 
ORTHOPAEDIC - Orthopaedic surgeries 
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LAPAROSCOPIC -   Laparoscopic surgeries 
UROLOGY        -   Urological surgeries 
10. DURS                     -  Duration of surgery 
11. DURA                     -  Duration of anaesthesia 
12. N1               -  Nausea at initial hour,  where  
                                                            1. NO - absence of nausea 
                                                             2. YES- presence of nausea 
13. SN1         -   Score of nausea at initial hour where 
                                                                       0= none 
                                                                        1=mild 
                                                                         2=moderate 
                                                                         3=severe 
14. N24        -  Nausea at 24 hours, where 
                                                      1. NO = absence of nausea 
                                                             2. YES = presence of nausea 
15. SN24       -   Score of nausea at initial hour where 
                                                                        0= none 
                                                                        1=mild 
                                                                         2=moderate 
                                                                         3=severe 
16. NRESCUE    -  Use of rescue antiemetic for nausea 
17. R1      -   Retching at initial hour,  where  
                                                       1. NO = absence of retch 
                                                             2. YES = presence of retch 
18. SR1   -  Score of retching at initial hour, where 
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                                                                       0= none 
                                                                         1=mild 
                                                                         2=moderate 
                                                                          3=severe 
19. R24   -  Retching at 24 hours, where 
                                                             1. NO = absence of retch 
                                                            2. YES = presence of retch 
20. SR24   -  Score of retching at 24 hour,  where 
                                                                       0= none 
                                                                        1=mild 
                                                                         2=moderate 
                                                                         3=severe 
21. RRESCUE  -  Use of rescue antiemetic for retching 
22. E1    -  Emesis at initial hour, where  
                                                      1. NO = absence of emesis 
                                                             2. YES = presence of emesis 
23. SE1   -  Score of emesis at initial hour, where 
                                                                       0= none 
                                                                        1=mild 
                                                                         2=moderate 
                                                                         3=severe 
24. E24   -  Emesis at 24 hours, where   
1. NO = absence of emesis 
                                                             2. YES = presence of emesis 
25. SE24      -  Score of emesis at 24 hour, where 
xiv 
 
                                                                       0= none 
                                                                        1=mild 
                                                                         2=moderate 
                                                                         3=severe 
26. ERESCUE        -  Use of antiemetic for emesis 
27. COMPLI       -  Complication 
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MASTER CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO. IP.No. ARM NAME AGE SEX Wt ASA SURGERY DurS DurA N1 SN1 N24 SN24 NRescue R1 SR1 R24 SR24 R.Rescue E1 SE1 E24 SE24 E.Rescue COMPLI
1 173793 1 Mr. Unni 47 M 65 I Head and neck 180 200 2. Yes 1 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
2 174202 1 Mrs. Mariya Azhagan 53 F 70 II Head and neck 150 170 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
3 174724 1 Mr.Mani 50 M 75 II Abdominal 90 115 2. Yes 2 1. No 0 1. No 1. No 0 1. No 0 1. No 2. Yes 2 1. No 0 1. No 0
4 176864 1 Mrs.Sinthiya 22 F 60 I OBG 120 140 2. Yes 1 2. Yes 1 1. No 1. No 0 2. Yes 1 1. No 2. Yes 1 1. No 0 1. No 0
5 177161 1 Mrs.Jessy 42 F 60 I Breast 30 50 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
6 178408 1 Mr.Teddy 42 M 70 I Abdominal 60 80 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
7 178243 1 Mr.Vishnu 25 M 62 I Abdominal 180 200 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
8 181997 1 Mrs.Vimala Devi 45 F 80 I Head and neck 150 190 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
9 178888 1 Mrs.Shanthi 48 F 89 I Abdominal 200 220 2. Yes 3 1. No 0 1. No 2. Yes 2 1. No 0 1. No 2. Yes 1 1. No 0 1. No 0
10 181422 1 Mr.Paul Raj 52 M 48 II Urological 40 60 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
11 182921 1 Mr.Yesuratham 53 M 60 II Head and neck 240 270 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
12 182931 1 Ms.Arebana 22 F 70 I Head and neck 220 250 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
13 182925 1 Mrs.Thajeetha Beevi 40 F 70 I Laproscopic 60 80 2. Yes 1 2. Yes 2 1. No 1. No 0 2. Yes 1 1. No 2. Yes 1 2. Yes 1 1. No 0
14 183136 1 Mrs.Lalithambika 34 F 54 II Laproscopic 60 85 2. Yes 1 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
15 183164 1 Mrs.Sasikala 32 F 52 II Laproscopic 60 80 2. Yes 2 1. No 0 1. No 1. No 0 1. No 0 1. No 2. Yes 1 1. No 0 1. No 0
16 185349 1 Mrs.Gomathy 39 F 52 II Laproscopic 60 85 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
17 178597 1 Mr.Mariya Pocoliyan 46 M 75 II Head and neck 95 115 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
18 181888 1 Mr.Albert 35 M 89 I Urological 120 150 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
19 185796 1 Mrs.Majeeba 34 F 50 I Head and neck 120 150 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
20 185507 1 Mrs.Shengabavati 38 F 70 I Breast 90 110 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
21 186398 1 Mrs.Santhya 23 F 52 I Abdominal 200 220 2. Yes 2 2. Yes 2 1. No 2. Yes 1 1. No 0 1. No 2. Yes 1 2. Yes 2 2. Yes 0
22 188225 1 Mr.Ajikumar 27 M 52 I Head and neck 90 110 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
23 187831 1 Mr.Arul Pomani 32 M 65 I ENT 110 135 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
24 189134 1 Mr.Abilash 22 M 60 I Head and neck 120 150 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No discomfort
25 189352 1 Ms.Asha 21 F 50 I Breast 50 75 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
26 189720 1 Mrs.Mahalekshmi 52 F 50 II Head and neck 120 140 2. Yes 1 1. No 0 1. No 1. No 0 1. No 0 1. No 2. Yes 1 1. No 0 1. No 0
27 190301 1 Mrs.Nabeesha 40 F 56 II Breast 100 120 2. Yes 1 1. No 0 1. No 1. No 0 1. No 0 1. No 2. Yes 1 1. No 0 1. No 0
28 191061 1 Mr.Ayyanswami 55 M 52 II Urological 120 150 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
29 191604 1 Mr.Mathew 60 M 76 II Ent 90 115 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
30 191159 1 Mrs.Saraswathy 49 F 53 I OBG 90 115 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
31 193192 1 Ms.Rajayya 50 F 43 I Ent 60 85 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
32 193007 1 Mrs. Mincy 24 F 70 I Orthopaedic 90 130 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
33 195273 1 Mr. Mohandas 39 M 60 I Head and neck 120 150 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
34 194805 1 Mrs.Kilbeth Beevi 53 F 70 II Head and neck 110 130 2. Yes 2 1. No 0 1. No 2. Yes 1 1. No 0 1. No 2. Yes 2 1. No 0 1. No 0
35 196217 1 Ms.Prabha 26 F 60 I Breast 50 65 N0 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
36 193820 1 Mr.Vijayakumar 64 M 57 II Urological 60 85 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
37 197118 1 Mrs.Saroja 38 F 50 I Head and neck 90 120 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
38 197120 1 Mr.Rajesh 20 M 60 I Abdominal 60 80 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
39 197488 1 Mr.Jayapaul 59 M 65 II Orthopaedic 90 110 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
40 200120 1 Ms.Kalpana 18 F 50 II Head and neck 90 120 2. Yes 2 2. Yes 2 1. No 2. Yes 1 1. No 0 1. No 2. Yes 2 1. No 0 1. No 0
41 199542 1 Mrs.Kumari Thaagam 45 F 62 I Head and neck 90 110 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
42 202756 1 Mr.Siddiq 32 M 60 II Abdominal 120 150 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
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 S.NO. IP.No. ARM NAME AGE SEX Wt ASA SURGERY DurS DurA N1 SN1 N24 SN24 NRescue R1 SR1 R24 SR24 R.Rescue E1 SE1 E24 SE24 E.Rescue COMPLI
43 166322 2 Vasudevan 65 M 60 II Urology 150 170 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
44 174114 2 Archana 22 F 59 I Laproscopic 90 120 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
45 174115 2 Beena Mol 26 F 61 I Laproscopic 90 110 2. Yes 2 2. Yes 2 1. No 2. Yes 1 2. Yes 1 1. No 2. Yes 1 2. Yes 2 2. Yes 0
46 174118 2 Shobha 33 F 60 II Ent 90 120 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
47 176715 2 Abser Khan 33 M 60 II Ent 120 150 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
48 176527 2 Ponnupillai 65 M 58 II Ent 120 140 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
49 185095 2 Deepa 31 F 58 I OBG 90 110 2. Yes 1 1. No 0 1. No 2. Yes 1 1. No 0 1. No 1. No 0 1. No 0 1. No 0
50 182280 2 Shaiba 29 F 70 I Laproscopic 60 80 2. Yes 1 1. No 0 1. No 2. Yes 1 1. No 0 1. No 2. Yes 1 1. No 0 1. No 0
51 182283 2 Sanjeetha 35 F 59 I Laproscopic 45 60 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
52 176676 2 Raguvan 26 M 60 I Abdominal 150 170 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
53 176272 2 Raveendran 30 M 50 I Head and neck 140 165 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
54 185452 2 Sasikala 31 F 45 I OBG 100 120 2. Yes 2 1. No 0 1. No 2. Yes 1 1. No 0 1. No 1. No 0 1. No 0 1. No 0
55 185463 2 Sajeela 32 F 65 II Ent 120 140 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No Headache
56 185578 2 Jerina Banu 25 F 75 I Laproscopic 90 110 2. Yes 1 2. Yes 1 1. No 2. Yes 1 1. No 0 1. No 2. Yes 1 1. No 0 1. No 0
57 177084 2 Sreekumar 48 M 60 I Urology 150 175 2. Yes 1 2. Yes 1 1. No 2. Yes 1 1. No 0 1. No 2. Yes 1 1. No 0 1. No 0
58 186940 2 Rekha 24 F 54 I Laproscopic 60 85 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
59 187548 2 Arumugam 43 M 54 II Ent 200 220 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
60 186693 2 Latha 30 F 41 I OBG 90 110 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
61 187800 2 Naveena 21 F 70 II Laproscopic 60 85 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
62 178430 2 Pallammal 58 M 70 II Orthopedic 120 145 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
63 180557 2 Ratheesh 27 M 65 II Orthopedic 180 200 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
64 180559 2 Murukesan 59 M 70 I Orthopedic 120 135 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
65 188684 2 Gayathridevi 29 F 61 I OBG 60 80 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
66 190198 2 Mini 25 F 50 I OBG 60 75 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
67 194858 2 Priya 32 F 61 I Laproscopic 60 80 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
68 199153 2 Saranya 24 F 52 I Abdominal 60 85 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
69 198625 2 Ponnamal 52 M 75 II Abdominal 90 110 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
70 198732 2 Jini 30 F 64 I Laproscopic 50 85 2. Yes 3 2. Yes 1 1. No 2. Yes 1 1. No 0 1. No 2. Yes 2 2. Yes 1 2. Yes 0
71 197661 2 Shincy 24 F 46 I Laproscopic 60 80 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
72 197582 2 Pradeep 19 M 45 I Ent 120 145 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
73 197012 2 Subith 18 M 66 I Ent 180 200 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
74 181159 2 Christhu Rajan 45 M 60 II Orthopedic 180 210 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
75 194828 2 Lekshmi 40 F 51 II Laproscopic 120 150 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
76 194975 2 Jenifa 25 F 44 I Laproscopic 60 75 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
77 201787 2 Usha 47 F 60 II Head and neck 100 120 2. Yes 1 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
78 202442 2 Mani 53 M 49 II Abdominal 120 140 2. Yes 2 2. Yes 1 1. No 1. No 0 1. No 0 1. No 1. No 0 2. Yes 1 1. No 0
79 202507 2 Krishnan 48 M 55 I Head and neck 120 150 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
80 202568 2 Sanal 19 F 50 I Head and neck 240 270 2. Yes 1 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
81 193008 2 Prasad 28 M 75 I Orthopedic 120 150 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
82 188222 2 Murugayan 60 M 55 II Orthopedic 60 80 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
83 189335 2 Sukumaran 44 M 60 I Head and neck 120 150 2. Yes 1 1. No 0 1. No 1. No 0 1. No 0 1. No 2. Yes 1 1. No 0 1. No 0
84 187739 2 Rajayyan 47 M 65 I Orthopedic 120 150 2. Yes 1 1. No 0 1. No 1. No 0 1. No 0 1. No 1. No 0 1. No 0 1. No 0
